Podcasts about CRISPR

V tokratni Frekvenci X se pogovarjamo z nesojenim nobelovcem, litovskim znanstvenikom Virginijusom Šikšnysom. Bil je eden prvih, ki je ugotovil mehanizem sistema CRISPR. Spoznali smo njegovo zgodbo in smolo z objavo članka ter se z dr. Romanom Jeralo s Kemijskega inštituta spraševali, kako težko je doseči objavo v pomembnih znanstvenih revijah, če prihajaš iz malega inštituta majhne evropske države, kot je Litva. In nenazadnje tudi Slovenija. Poglavja: 00:21:20 Xpertiza: Domen Vreš

Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. Today, we explore a series of groundbreaking advancements and strategic collaborations that promise to transform drug development and patient care.In the autoimmune space, Boehringer Ingelheim has made a significant move by securing a $570 million agreement with CDR-Life. This deal centers on a trispecific antibody, a novel therapeutic approach that targets multiple pathways simultaneously, potentially revolutionizing treatments for autoimmune diseases. Boehringer's commitment to these cutting-edge modalities highlights their strategy to leverage novel technologies for more effective therapeutic solutions.Similarly, Celltrion has entered a $744 million collaboration with Kaigene, focusing on two preclinical autoimmune drugs. This partnership marks Celltrion's strategic shift from biosimilars to novel biologics, positioning the company at the forefront of biologic therapeutics. By investing in early-stage research, Celltrion aims to introduce transformative therapies for autoimmune conditions, showcasing the industry's willingness to bet on groundbreaking scientific advancements.In gene editing, Azalea Therapeutics is gaining attention with its focus on permanent genome editing using a dual-vector approach. Backed by $82 million in funding and support from CRISPR pioneer Jennifer Doudna, Azalea is poised to develop potentially curative solutions through single-dose treatments. The credibility lent by a Nobel laureate adds anticipation to their research outcomes, with the potential to significantly impact gene therapy.Shifting focus to clinical trials, Sarepta Therapeutics faces challenges after missing the primary endpoint in its confirmatory trial for Duchenne muscular dystrophy drugs. Despite this setback, Sarepta is pursuing full FDA approval, emphasizing the complex interplay between clinical data and regulatory strategies. This situation underscores the critical importance of robust confirmatory trials in securing drug approvals and ensuring patient access to new therapies.Merck is making strategic moves in oncology by regaining full control over an early-phase asset and securing $700 million from Blackstone for its oncology pipeline. This dual focus on asset acquisition and financial fortification reflects Merck's aggressive growth strategy aimed at expanding its cancer treatment offerings.Emerging from stealth mode, Neok Bio has secured a $75 million investment to advance bispecific antibody-drug conjugates into clinical trials. These bispecific ADCs represent the forefront of targeted cancer therapies, aiming for precision targeting of cancer cells while minimizing off-target effects. Neok Bio's progress could significantly enhance oncology treatment paradigms through improved therapeutic indices.Turning to regulatory landscapes, Teva's recall of over half-a-million bottles of prazosin hydrochloride due to potential carcinogenic impurities highlights ongoing challenges in ensuring drug safety and quality control within manufacturing processes. Such recalls underscore the critical importance of maintaining high standards in pharmaceutical production.In broader industry developments, we see dynamic trends where scientific innovation meets strategic business decisions and regulatory considerations. The potential impact on patient care is profound, with breakthroughs in autoimmune treatments, gene editing technologies, and targeted cancer therapies poised to alter therapeutic landscapes significantly.UCB has achieved another milestone with FDA approval for Kygevvi, an ultra-rare disease medication marking their third approval in rare conditions within three years. This success underscores UCB's strategic focus on niche markets that offer less competition but significant patient impact. Advancements in genetic research aSupport the show

To Find Deplorable Janet--> https://open.spotify.com/show/3K5Xi9LugxNdI06GXSIjAp?si=m5hPD7OsS6eim1jACk84ewTo sign up for our Patreon go to-> Patreon.com/cultofconspiracypodcast To Join the Cajun Knight Patreon---> Patreon.com/cajunknight To Find The Cajun Knight Youtube Channel---> click hereTo Invest In Gold & Silver, CHECK OUT—-> Www.Cocsilver.com 10% OFF Rife Machine---> https://rifemachine.myshopify.com/?rfsn=7689156.6a9b5c To find the Meta Mysteries Podcast---> https://open.spotify.com/show/6IshwF6qc2iuqz3WTPz9Wv?si=3a32c8f730b34e79 50% OFF Adam&Eve products---> :adameve.com (promo code : CULT) To Sign up for our Rokfin go to --> Rokfin.com/cultofconspiracy Become a supporter of this podcast: https://www.spreaker.com/podcast/cult-of-conspiracy--5700337/support.

We've entered a new age. Where nature once took a million years to make a few genetic changes, scientists can now make billions in an afternoon — and even imagine adapting humans for life beyond Earth.George Church, a Harvard geneticist, pioneer of the Human Genome Project, and founder of more than 50 biotech companies, helped lay the foundation for CRISPR, personal genomics, and even de-extinction.In this episode, he explains how biotechnology, AI, and materials science are converging to transform life itself -  from reversing aging and curing disease to resurrecting lost species like the woolly mammoth, and one day, helping humanity thrive among the stars.

There's so much incredible research and work that happens every day at UC Berkeley, on everything from artificial intelligence and quantum computing to linguistics and the study of social justice. It holds the record for the most Nobel Prize winners among any public university in the world, with two wins just this year.This work can be highly theoretical and technical, taking decades to fully develop. Yet its impact extends far beyond academia, leading to world-changing results, from the invention of CRISPR gene editing that has saved lives to ethnic studies courses that foster a stronger sense of identity and critical consciousness. Within these broad impacts are millions of stories of how Berkeley's research has transformed society. In this season of Berkeley Voices, we hear two sides of a story — from Berkeley scholars working on life-changing research, and from the people who've been changed by it.New episodes will come out on the first Thursday of each month, from November through April. Listen to Berkeley Voices on your favorite podcast app or on YouTube @BerkeleyNews. You can find all of our podcast episodes, with transcripts and photos, on UC Berkeley News at news.berkeley.edu/podcasts.Listen to the episode and read the transcript on UC Berkeley News (news.berkeley.edu/podcasts/berkeley-voices).Music by Blue Dot Sessions.UC Berkeley design by Neil Freese. Hosted on Acast. See acast.com/privacy for more information.

This week, Brent speaks with Sir Adrian Bird, the pioneering geneticist whose discoveries on DNA methylation reshaped our understanding of how genes are regulated. Bird explains what DNA methylation actually is and why he's skeptical of popular claims that it determines "biological age" or can be easily hacked to reverse aging. They discuss his groundbreaking work on Rett syndrome, how CRISPR gene editing is being used in clinical trials to potentially cure it, and what that might mean for other neurological diseases. He's a wonderful guest. Hope you enjoy.

Grab your consent forms (but don't sign them yet) and your government-issued fetal monitoring bracelet, because today we're getting a broader understanding of what happens when people aren't treated like people but like data, vessels, and experiments. The body keeps the score- even when it's for medical horror stories. From Adriana Smith, kept alive against her will to serve as a human incubator under Georgia's abortion laws, to Henrietta Lacks, whose cells were stolen, immortalized, and monetized without her knowledge or family's consent, this episode unpacks the long, horrifying legacy of unethical medical research in America.We'll walk through the Tuskegee Syphilis Study, the Holmesburg Prison experiments, the HIV-tainted blood scandal that infected kids like Ryan White, while the government spent more money on the Tylenol murders than AIDS research. And this isn't ancient history, it's happening today- not just with Adriana Smith, or Terri Schiavo as a human prop before her but with forced sterilizations, CRISPR babies, and what happens when “the greater good” doesn't include you.This isn't an anti-science episode. I'm pro-science, but not when the most marganilzed among us have to die for it. And in a world where women, people of color, and the poor are still being used, sometimes even after death- it's more important than ever to ask:Who gets to be a patient? And who's just a test subject?(Originally released May 2025)Become a supporter of this podcast: https://www.spreaker.com/podcast/broads-next-door--5803223/support.

BRAIN Biotech AG Deep Dive: Key TakeawaysIn this exclusive deep dive, Michael Schneiders, CFO of Brain Biotech AG, takes on the seven most frequently asked questions from institutional investors — offering clarity, conviction, and a forward-looking view on everything from AI-driven enzyme discovery to U.S. expansion, M&A, and the commercial pipeline within the BioIncubator portfolio.Let's unpack the key investor topics that matter most to understanding Brain Biotech's current strategy and its long-term value-creation potential.1. What are Enzymes, and Why Are They So Attractive?Enzymes are natural proteins that catalyze biochemical reactions, and Brain Biotech focuses on microbial enzymes with industrial and human applications. Why does this matter to investors? Because enzymes offer low-energy, biodegradable, and sustainable alternatives to chemical synthesis — making them key tools in the green industrial transformation.The global enzyme market stands at €6 billion, growing at mid-single-digit rates with strong margins. Consumers prefer natural enzyme-based solutions, especially in food, nutrition, and life sciences. Brain, with its unique position and strategic focus, is well-positioned to lead this trend.2. What Sets Brain Biotech Apart from Other Industrial Biotech Firms?Michael Schneiders emphasizes Brain's end-to-end platform—from discovery and AI-assisted enzyme design, to development, fermentation, and production. Few players can offer the full value chain. This integrated model serves three verticals:ProductsProprietary enzymes for food & life science.CDMOContract manufacturing for biopharma clients.CROCustom research in enzyme innovation.This makes Brain not just a supplier, but a strategic co-developer with its clients — increasing stickiness, value creation, and margin expansion.3. How Is AI Revolutionizing Enzyme Discovery at Brain?Brain's AI and machine learning platforms are now central to its enzyme innovation engine. Their proprietary platform, “MetXtra,” enables the discovery and synthetic design of novel enzymes, with 99% of the sequences unique to public databases.With bioinformatics, machine learning, and CRISPR gene editing, Brain is accelerating timelines from idea to prototype, cutting costs, and driving customer success. Their goal: design enzymes that don't yet exist in nature—customized for client needs.This digital-first approach is transforming Brain into a tech-enabled biotech innovator—and investors are taking notice.4. What Are Brain's Medium-Term Growth Targets, and What Role Does M&A Play?Brain's mid-term goal is to double enzyme segment sales through high-single-digit to low-double-digit organic growth. The addressable market for their core activities is approximately €2 billion — and with only €50 million in sales today, there's massive upside.Brain also aims to lift its adjusted EBITDA margin from 10% to 15%, unlocking operational leverage as scale increases.While organic growth is the priority, Brain remains opportunistic on M&A—with a successful track record including Biocatalysts, RareTech, and AnalytiCon Discovery. One more medium-sized acquisition (à la Biocatalysts) is planned within the next 5 years. ..▶️ Other videos: Elevator Pitch: https://seat11a.com/investor-relations-elevator-pitch/Company Presentation: https://seat11a.com/investor-relations-company-presentation/ Deep Dive Presentation: https://seat11a.com/investor-relations-deep-dive/Financial Results Presentation: https://seat11a.com/nvestor-relations-financial-results/ ESG Presentation: https://seat11a.com/investor-relations-esg/ T&C This publication is intended solely for informational purposes and does not constitute investment advice. By using this website, you agree to our terms and conditions as outlined on www.seat11a.com/legal and www.seat11a.com/imprint.

Investigadores britânicos usaram o Crispr para eleminar o gene que torna as bananas castanhas. As novas bananas devem chegar ao mercado em 2026

Emily is an Assistant Professor at MDI Biological Laboratory where she studies neurodegenerative disease-associated genes using super-resolution imaging of living, adult worms. Emily earned her Ph.D. at the University of Maine while embedded in the Jackson Laboratory and during her post-doc at MDI Bio Lab, she was recognized by the National Institutes of Health as an “Outstanding Scholar in Neuroscience”.This conversation was recorded in September 2025. ~~~~~The Maine Science Podcast is a production of the Maine Discovery Museum. It is recorded at Discovery Studios, at the Maine Discovery Museum, in Bangor, ME. The Maine Science Podcast is hosted and executive produced by Kate Dickerson; edited and produced by Scott Loiselle. The Discover Maine theme was composed and performed by Nick Parker. To support our work: https://www.mainediscoverymuseum.org/donate. Find us online:Maine Discovery MuseumMaine Discovery Museum on social media: Facebook Instagram LinkedIn Bluesky Maine Science Festival on social media: Facebook Instagram LinkedInMaine Science Podcast on social media: Facebook Instagram © 2025 Maine Discovery Museum

Krauter, Ralf www.deutschlandfunk.de, Forschung aktuell

Humans and nature have always coexisted. But, human intervention makes our modern world look very different than it once did. This episode, host Dr. Samantha Yammine digs into how humans are reshaping the wild. Sam speaks to Dr. Harland Patch about the decline of insect populations around the world and how we can provide better environments for pollinators. She also dives into the world of CRISPR gene editing among Argentinian polo horses and why so many people seem to be getting diagnosed with Lyme disease. Link to Show Notes HERE Follow Curiosity Weekly on your favorite podcast app to get smarter with Dr. Samantha Yammine — for free! Still curious? Get science shows, nature documentaries, and more real-life entertainment on discovery+! Go to https://discoveryplus.com/curiosity to start your 7-day free trial. discovery+ is currently only available for US subscribers. Hosted on Acast. See acast.com/privacy for more information.

In questa nuova puntata non possiamo non cominciare ringraziando gli ascoltatori che sono venuti a trovarci nella grigia Ginevra per una giornata con visita al CERN, alla città, e tradizioni culinarie a base di latticini! C'è chi dice che sia stata una bellissima giornata e c'è chi mente.Tornando alla scienza si realizza finalmente il sogno di Valeria, perché la puntata si apre con Francesca che parla di virus! Un nuovo preprint pubblicato dai ricercatori di Stanford ha sfruttato l'intelligenza artificiale per progettare nuovi batteriofagi in grado di infettare uno specifico ceppo di E. Coli. Diversi fagi sono stati sintetizzati e sono risultati infettivi e specifici! Nell'attesa che l'articolo sia pubblicato, questa potrebbe essere una nuova frontiera per la terapia fagica che è una delle armi a disposizione per combattere la resistenza agli antibiotici.Leonardo in esterna intervista Marco Giordani, professore di telecomunicazioni all'Università di Padova che ci spiega alcune sfide tecnologiche dietro alle moderne reti satellitari, continuando l'approfondimento iniziato la scorsa settimana.Tornati in studio, dopo una barza statisticamente brutta, Valeria ci parla di un nuovo articolo pubblicato su Nature, in cui viene identificato un nuovo recettore per TBEV, il virus dell'encefalite da zecche. Questa proteina, chiamata LRP8, è necessaria al virus per entrare nelle cellule ed è presente nelle cellule del sistema nervoso. I ricercatori, dopo aver verificato l'interazione specifica tra il virus e la proteina, hanno anche sviluppato una forma di recettore solubile che è capace di legarsi al virus e prevenire l'infezione nelle cellule e anche nei topi.Diventa un supporter di questo podcast: https://www.spreaker.com/podcast/scientificast-la-scienza-come-non-l-hai-mai-sentita--1762253/support.

Imaginez la scène : un poisson préhistorique, il y a des centaines de millions d'années. À cette époque, pas de doigts, pas de mains, juste des nageoires. Et pourtant, selon une étude publiée le 17 septembre 2025 dans la revue Nature, c'est dans cette créature aquatique qu'il faut chercher l'origine… de nos doigts. Et, encore plus étonnant, le secret se cache dans un organe qu'on n'aurait jamais soupçonné : son anus, ou plutôt son cloaca, cette ouverture unique qui servait à la fois à digérer, à uriner et à se reproduire.L'étude a révélé quelque chose de fascinant. Les chercheurs ont identifié un ensemble de séquences génétiques appelées “paysages régulateurs”. Ces petites régions d'ADN ne fabriquent pas de protéines, mais elles contrôlent l'activité de gènes essentiels. Parmi eux, les gènes Hox, qui orchestrent le développement du corps chez l'embryon. Or, chez les poissons, ce fameux paysage régulateur n'était pas du tout lié aux nageoires. Il était actif dans la formation du cloaca.Avec l'outil CRISPR, les scientifiques ont fait une expérience cruciale. Quand ils suppriment ce paysage régulateur chez la souris, les doigts et les orteils ne se forment pas correctement. Mais quand ils le suppriment chez un poisson, les nageoires se développent normalement… tandis que le cloaca, lui, est gravement perturbé. Autrement dit, la machinerie génétique qui a servi à construire nos doigts venait à l'origine d'un système utilisé pour bâtir un orifice digestif.C'est un exemple parfait de ce que les biologistes appellent la co-option évolutive. L'évolution n'invente pas à partir de rien. Elle réutilise des circuits anciens, elle détourne des mécanismes existants pour leur donner une nouvelle fonction. Dans ce cas, un “programme génétique” d'abord destiné au cloaca a été recyclé pour façonner des doigts lorsque nos ancêtres ont quitté l'eau pour marcher sur la terre ferme.Alors, quand vous bougez vos mains ou quand vous pianotez sur un clavier, souvenez-vous que ce geste quotidien porte la trace d'une histoire bien plus ancienne qu'on ne l'imagine. Vos doigts ne sont pas seulement les héritiers des nageoires d'un poisson, mais aussi le fruit d'un bricolage génétique qui, il y a très longtemps, concernait… un anus préhistorique. Voilà une image inattendue, presque poétique, qui nous rappelle à quel point l'évolution sait transformer le trivial en extraordinaire. Hébergé par Acast. Visitez acast.com/privacy pour plus d'informations.

Lords: * Danny * https://nightbrunchband.com/ * Walker * https://nightbrunchband.com/ Topics: * You Probably Think This Song is About You * The Perfect r/crappymusic Post: An audio tour of Archetypes * https://media24.fireside.fm/file/fireside-uploads-2024/images/3/3597ddeb-e52e-4cda-a59c-c64600489fea/0291r0zf.png * https://www.youtube.com/watch?v=6EIwP0zerbk * Sample-based film scores in the 80s * https://www.tumblr.com/mogwaipoet/786937779224461312/terminator-2-1991-and-the-princess-bride-1987 * Do Not Stand at My Grave and Weep, by Clare Harner actually * https://en.wikipedia.org/wiki/DoNotStandatMyGraveand_Weep * Being a Video Game Newb in Your 40s Microtopics: * Is it a Topic or is it Just Banter? * Cleaning Lords, Lunch Lords and Cat Lords. * Have you heard the good word about the Gaylady? * Night Brunch. * Wearing your own band's t-shirt. * A thing that could happen for a while and then was no longer able to happen. * Hi Cindy! * Motivating yourself to work harder via self loathing. * Feeling the need to act all angsty so that people take you seriously as an artist. * A Touch of Grandiosity. * How many tracks get uploaded to SoundCloud every day? * Continuing to discover music from the 1970s. * It's called "Topic Lords," not "Correct Lords." * Once it becomes impossible to make new music, and we go back and start listening to all the SoundCloud uploads with 0 listens. * All the kids at Rock & Roll Camp getting excited about Lofey. * Pretending a topic is about one thing when it's actually about something else. * Canadian Actor Dave Coulier. * Tuesday at 3:01pm. * Learning a new chord on your Electric Tenor Guitar. * Bringing Pokemon Puzzle League characters into your love song. * Having a whole week to dial in that wub wub patch. * What art is for and what art should be for. * Fun is our only reward. * The objective best pitch wheel range. * The Funky Worm preset. * Synthesizers that can save and load patches but only when plugged into your phone. * Coming up with a Rube Goldberg machine to upload patches from a web server to your CZ-5000. * thisdx7cartridgedoesnotexist.com * In a convex optimization problem, there is no gradient to descend. * Fiddling with the synthesizer sliders until you reach a corner of the parameter space that doesn't make any noise and giving up. * Camp Counselor Grant hastily drawing all the synthesizer waves on the board. * Ask any Geometer, the triangle has three sides. Love triangles are actually just two love segments. * The All Topic Fakeouts episode. * The gulf between how an artist thinks they're presenting themselves and how they're being received. * A Beautiful Rainbow of the Human Experience. * Elderly rappers with excellent flow but terrible drip. * Piling onto propaganda music. * Someone doing their own thing with confidence and authenticity. * Graffiti with immaculate copyediting. * With improved access to art tools, taste is one of the only things left to get wrong. * Only the best crappy music. * Promoting your music in r/crappymusic. * Tori the Clown Rap Gal. * The audacity of extreme autotune. * All Youtube thumbnails converging on the same cognitive attention hacks. * Singing the comments on your last video. * Situations where echo chamber amplification is fun and good for the world. * Obscure Music That Slaps. * Serbian Kolos. * The Ketron Event Chrom. * The Nightmare Klaxon that Represents Dread. * All the Fairlight CMI presets used in the Terminator 2 soundtrack. * Growing up playing samples at every possible speed in Impulse Tracker. * Slowly sucking dog food out of a can to simulate the sound of a mimetic polyalloy passing through steel bars. * It's been a long day and you're ready to go home but you need to slam 1000 more inverted glasses into bowls of yogurt, let's hurry it up guys. * That one sample library squeaking metal door sound that everyone uses. * Calling out comb filtering whenever you hear someone exhale deeply while sitting down at a desk. * The sound guy instructing all the actors when to breathe to minimize comb filtering. * Rubber Baby Knopfler Romplers. * All the things you are after you die. * The purpose of suffering. (So we can write cool poems about it.) * Making art about how trauma used to exist. * Why wireheading will not solve our problems. (Because everything uses bluetooth now.) * Who needs trauma when we have CRISPR? * Shepherding noobs. * Play Any Video Game Day. * Complicated goose controls. * Trying to play Portal as your first 3D game. * Learning video games vs. learning board games. * Trying to get into video game series that don't change. * Looking at the screen and/or ants until it coalesces into an image. * Video games filled with really gross blood squirt sounds. * Jumping on and off of buildings. * Playing Breath of the Wild and just collecting mushrooms and herbs. * Grass simulation in Breath of the Wild vs. in Horizon Zero Dawn. * Putting yourself in the head-space of the protagonist in order to do protagonist stuff. * Spelling brunch the secret way.

When Jesus said the End Times would be as the Days of Noah, one thing He was getting at is genetic tampering with the human race Pastor Gene Pensiero Find audio, video, and text of hundreds of other prophecy updates at: https://calvaryhanford.com/prophecy Read along with us at https://calvaryhanford.substack.com Follow us on YouTube at https://youtube.com/calvaryhanford — […]

Discover the journey of a biomedical pioneer whose curiosity, grit, and innovation have shaped global healthcare—from CRISPR to mRNA vaccines, regenerative medicine, and AI-driven discoveries. Learn how science can transform lives and inspire the next generation of innovators.00:09- About Dr Bob LangerDr. Langer is an American chemical engineer, scientist, entrepreneur, inventor and one of the twelve Institute Professors at the Massachusetts Institute of Technology. 

Join Dr. Paloma Giangrande, Editor-in-Chief of Molecular Therapy Nucleic Acids, as she discusses a recently published MTNA article, Controlling CRISPR-Cas9 genome editing in human cells using a molecular glue degrader, with its authors Drs. Krishanu Saha and Namita Khajanchi (UW-Madison). If you enjoy this episode, check out our hybrid event this fall that will allow you to engage with pioneering researchers in gene editing! Breakthroughs in Targeted In Vivo Gene Editing will be held in San Diego and virtually November 20-21, 2025. Music: 'Electric Dreams' by Scott Buckley - released under CC-BY 4.0. www.scottbuckley.com.auShow your support for ASGCT!: https://asgct.org/membership/donateSee omnystudio.com/listener for privacy information.

In the four years since the book’s publication, CRISPR has revolutionized the world of medical treatments and possibilities. But our world has changed drastically, too. As AI’s impact grows, U.S scientists are facing funding cuts like never before. For our final episode, we bring you a live conversation between Walter Isaacson and Jennifer Doudna at the New Orleans Book Festival. In her own words, you’ll hear Doudna explain how CRISPR blossomed from an idea to a phenomenon, and the challenges scientists faces in this politically fraught moment.See omnystudio.com/listener for privacy information.

In this inspiring episode, Dr. Felipe Gálvez-Cancino, group leader at Oxford's Center for Immuno-Oncology, walks us through his team's groundbreaking research on macrophages, T cells, and immune regulation in solid tumors. Tracing his path from early cancer vaccine work to advanced antibody-dependent cellular phagocytosis (ADCP), Felipe shares how his team is working to reprogram tumor-associated macrophages to more efficiently eliminate cancer cells.He explains how regulatory CD4+ T cells suppress both T cell and macrophage responses within tumors and how removing that suppression can supercharge phagocytic function. We also hear how his lab is leveraging mouse models of hepatocellular carcinoma, clinical samples, and modern molecular biology techniques (like in vivo liver transfection and CRISPR-ready plasmid engineering) to study intratumor heterogeneity and antigen spreading.Felipe also reflects on the value of early molecular biology training—like mastering gigapreps—and emphasizes the importance of curiosity, persistence, and collaboration in scientific careers. Whether you're interested in cancer biology, immunotherapy, or just passionate about translating discoveries into new therapies, this episode offers both technical depth and motivational insight. Subscribe to get future episodes as they drop and if you like what you're hearing we hope you'll share a review or recommend the series to a colleague.  Visit the Invitrogen School of Molecular Biology to access helpful molecular biology resources and educational content, and please share this resource with anyone you know working in molecular biology. For Research Use Only. Not for use in diagnostic procedures.

A public murder, a public act of forgiveness, and a public reckoning with what courage really costs—this conversation starts where the news won't and moves into the places most of us live: trust, discernment, and the daily habits that shape our conscience. We open with the assassination of Charlie Kirk and the surprising witness that emerged from the memorial—clear gospel, costly grace, and a reminder that God can draw purpose from tragedy without excusing evil. The question beneath the headlines is personal: what risks will we take for truth, and how do we respond when our enemies give us every reason not to love them?From there, we move through the thickets of modern medicine, where vaccine skepticism collides with scientific claims and shifting guidance. Instead of trading slogans, we slow down to practice discernment—separating correlation from causation, weighing evidence, and remembering that loving our neighbor includes doing our homework. That same careful posture anchors a frank look at xenotransplantation, as researchers push the boundaries of pig-to-human organ transplants. We unpack somatic versus germline concerns, the special dignity of human life, and how to balance innovation, transparency, and moral guardrails when the stakes are life and death.Finally, we tackle AI's ethical drift. New studies show the more people rely on AI, the easier cheating becomes and the harder it is to think for ourselves. We share practical ways to use AI without losing integrity—designing assessments that test real understanding, cultivating intellectual friction, and resisting the algorithmic echo chambers that tell us only what we want to hear. Through it all, one thread remains: a call to rebuild the muscles of clear thinking, mercy, and courage so we can serve our neighbors and witness to Christ with honesty and hope.If this resonates, subscribe, share it with a friend, and leave a review to help others find the show. Then tell us: which topic do you want us to dig into next?SHOW NOTES:Pig Lung Xenotransplant to Human: Chinese scientists have successfully transplanted a pig lung into a human being for the first time, with the organ partially functioning before it was removed. Researchers used CRISPR technology to make six gene edits to the left lung of a pig whose organs are roughly human-sized. They transferred the lung into a brain-dead 39-year-old man. Initially, the lung delivered oxygen to his blood and removed carbon dioxide. Within 24 hours, however, signs of damage appeared, and the body began to reject the organ. Scientists ended the experiment following fluid buildup. The patient was removed from life support per his family's wishes. (Source: https://tinyurl.com/24ccpehj  accessed 8-26-25)Which Diseases Will You Have in 20 Years? Using AI Increases Unethical Behavior Support the showThe ministry of Christian Life Resources promotes the sanctity of life and reaches hearts with the Gospel. We invite you to learn more about the work we're doing: https://christianliferesources.com/

In this episode, I talked to Dr. Alexander Marson, cofounder of Arsenal Biosciences and director of the Gladstone-UCSF Institute of Genomic Immunology. He is one of the pioneers of non-viral T-cell editing and is a serial biotech entrepreneur. We talked about Car T-cell Therapy, using CRISPR to edit T-cells, biotech, and his collaboration with Sean Parker, cofounder of Napster. ---------------------------------------------------------------Thanks to the sponsors:Audible: Use my link for a 30-day free trial: http://audibletrial.com/diamondgoatNewsly: https://newsly.mepromo code to receive a 1-month free premium subscription: EARLYMORNING Libysn: https://libsyn.compromo code: DG Dubby Energy: https://www.dubby.ggpromo code for 10% off: DIAMONDGOATOpus Clips:  https://www.opus.pro/?via=diamondgoat----------------------------------------------------------------------------------Listen on:Podcast website: https://www.spreaker.com/podcast/dg-early-morning-show--5943922Spotify: https://open.spotify.com/show/0EuhA6WyuerHtVAqcFrFeOPodcast YT channel clips: https://www.youtube.com/@dgearlymorningshowTiktok: @dgearlymorningshowApple Podcast: https://podcasts.apple.com/us/podcast/dg-early-morning-show/id1575451533Amazon Music: https://music.amazon.com/podcasts/f050b86c-1dad-4bc3-b12f-6aa5fa62438c  Goodpods: https://goodpods.com/podcasts/dg-early-morning-show-211830RadioPublic: https://radiopublic.com/dg-earlymorning-show-WoML4rBreaker: https://www.breaker.audio/dg-early-morning-showReason: https://reason.fm/podcast/dg-earlymorning-show--------------------------------------Check out my other stuff:Instagram: @itzdiamondgoatTwitter: @lildiamondgoatMain YT channel: youtube.com/diamondgoatTiktok: @lildiamondgoatSoundcloud: @Lil DiamondgoatSpotify: @Lil DiamondgoatMerch store: https://diamondgoat.creator-spring.com

Broadcast from KSQD, Santa Cruz on 10-02-2025: Dr. Dawn opens by explaining how blood pressure treatment guidelines have been corrected back to 140/90 after the problematic 2015 SPRINT study temporarily changed recommendations to 120/80. That study used ideal measurement conditions - five minutes of quiet sitting, perfect cuff sizes, compliant patients - creating unrealistic targets that caused elderly patients to faint and break hips. The Veterans Administration and major cardiology organizations now recommend treating to 140/90, with statins only for LDL above 190 or 12% ten-year cardiovascular risk. An emailer asks about claims linking Tylenol to autism. Dr. Dawn thoroughly debunks this, explaining that Swedish studies of 2.5 million children found no association when controlling for sibling comparisons. She notes autism rates remained flat from 1960-1990 despite widespread Tylenol use, then spiked after DSM-4 in 1994 and DSM-5 in 2013 broadened diagnostic criteria. Recall bias skews studies since mothers of autistic children are asked leading questions about past Tylenol use during pregnancy when fever treatment was medically necessary. She discusses RFK Jr.'s mixed positions, comparing him to Isaac Newton who excelled at physics but believed in astrology. While criticizing vaccine misinformation, Dr. Dawn strongly supports RFK's stance on ultra-processed foods. She describes NIH researcher Kevin Hall's studies showing people consume 500 extra calories daily on ultra-processed diets versus whole foods, even when nutrients are matched. The US produces 15,000 calories per person daily, with the food industry engineered to promote overconsumption through hyper-palatable fat-sugar-salt combinations. A caller asks about Healthcare 4.0 plans for biometric tracking bracelets and digital twins. Dr. Dawn discusses privacy concerns around constant health monitoring and data collection, noting that while early disease detection could be valuable, mandatory participation raises serious civil liberties issues. She acknowledges voluntary research projects like the Million Man Study but emphasizes the importance of consent and protection against unauthorized data access by advertisers or government agencies. An emailer shares research on ultrasound brain stimulation helmets as alternatives to surgical electrode implants. Dr. Dawn explains how 256-element phased ultrasonic arrays can target brain regions like the visual cortex with high precision mechanical perturbation, potentially treating Parkinson's, Alzheimer's, and depression without surgery. The technology remains experimental, requiring MRI guidance, but could become portable and dramatically improve quality of life for neurological conditions currently requiring invasive deep brain stimulation. A caller with adrenal cancer asks about fasting-mimicking diets. Dr. Dawn explains that 14-hour fasting before chemotherapy improves outcomes because healthy cells can downshift metabolism while cancer cells cannot. Cancer cells rely only on glycolysis without mitochondrial function, making them vulnerable during fasting states. She recommends chronotherapy - scheduling treatments during fasting periods - and expresses optimism about new cancer therapies like CAR-T cells and CRISPR technologies. An emailer asks about inulin fiber for fatty liver disease. Dr. Dawn explains how this fiber found in chicory, Jerusalem artichokes, and root vegetables stimulates gut bacteria to break down fructose before it reaches the liver, preventing fructose-induced hepatic lipogenesis. Inulin supplementation protects against fatty liver disease, increases antioxidant production, and helps with obesity by reshaping the gut microbiome to better process dietary sugars.

Sarah Aswegan, a seasoned biopharma leader and strategic advisor for global rare disease solutions, shares her journey from sales in pharma to her consulting work today. She discusses her experience in transitioning biopharma companies from clinical to commercial success, the evolution of medtech in diagnosing and managing rare diseases, and the collaborative efforts required to bring innovative treatments to market. She also shares insights on current trends in gene therapy, the dynamics of funding, and the importance of data in advancing care for rare disease patients. Guest links: www.saraaswegan.com  Charity supported:  Interested in being a guest on the show or have feedback to share? Email us at theleadingdifference@velentium.com.  PRODUCTION CREDITS Host & Editor: Lindsey Dinneen Producer: Velentium Medical   EPISODE TRANSCRIPT Episode 065 - Sara Aswegan [00:00:00] Lindsey Dinneen: Hi, I'm Lindsey and I'm talking with MedTech industry leaders on how they change lives for a better world. [00:00:09] Diane Bouis: The inventions and technologies are fascinating and so are the people who work with them. [00:00:15] Frank Jaskulke: There was a period of time where I realized, fundamentally, my job was to go hang out with really smart people that are saving lives and then do work that would help them save more lives. [00:00:28] Diane Bouis: I got into the business to save lives and it is incredibly motivating to work with people who are in that same business, saving or improving lives. [00:00:38] Duane Mancini: What better industry than where I get to wake up every day and just save people's lives. [00:00:42] Lindsey Dinneen: These are extraordinary people doing extraordinary work, and this is The Leading Difference. Hello and welcome back to another episode of The Leading Difference podcast. I'm your host Lindsey, and today I'm delighted to welcome to the show, Sarah Aswegan. Sarah is a seasoned biopharma leader helping organizations transition and grow from clinical to commercial success. She prides herself on the success of leading multiple global cross-functional teams and contributing to the success of the franchise areas she oversaw and served. Until recently, she's applied these experiences while serving in a consultancy capacity for many small to midsize biotechs entering or expanding in rare disease. She has also successfully helped organizations to start and scale adjacent spaces to biopharma, and most recently has been serving as a Global Head of Commercial Assets, Brands, and Care Solutions, and has led transformational change at UCP, having been part of the design and scale of the business unit for rare disease. She maintains a strong network among clinicians, access, bioethicists, and patient advocacy globally. Well, thank you so much for joining us today. I'm so excited to speak with you. [00:01:52] Sara Aswegan: Thanks, Lindsey. It's nice to be here. [00:01:54] Lindsey Dinneen: Wonderful. Well, I'd love, if you wouldn't mind, sharing a little bit about yourself and your background and what led you to medtech. [00:02:02] Sara Aswegan: Yeah, thanks Lindsey. You know, I, I started my career ages ago in the pharma side of things, and as my career has grown, so has the exposure across pharmaceuticals, into biotech and including aspects of medtech. As we look at some of the areas I've spent the last 18 years in rare disease, the medtech component is coming in largely around if we think about the diagnosis component and then the management of the different conditions over the lifespan of a child or adult affected by a rare condition. You can see things really evolving. I started my career on the sales side of things. My education is in business and communication, so anyone can learn the science if you have good mentors and people to help you along the way. And I was really, really fortunate to work amongst a team of amazing individuals, both in the US and then now having lived away for about 15 years outside of the US that have helped open my eyes to what can be possible and the differences by markets. And as I mentioned, I spent the last 18 years in the rare disease space really helping companies of all sizes build out and scale their teams, bringing in new assets and bringing solutions to the field of rare disease. And it's something I'm very passionate about. [00:03:06] Lindsey Dinneen: Yeah. Well, thank you for sharing a little bit about that. So I'm curious, that's a very specific niche and I would love to understand how you arrived at that and how you realized, "Oh, this is what I'm meant to be doing." [00:03:19] Sara Aswegan: Yeah. So I made a move geographically and company-wise to a small firm at the time. We were just a very small team. We called it the bootstrapping team at Shire Human Genetic Therapies, and I moved from the Chicago area to Boston, and that was my first really exposure to rare diseases. And, it's a completely different field and it continues to evolve even to this day. But the closeness and proximity you have to patients and their families and those with unmet need. And I have, you know, a couple of close friends as well as a family member that's been affected by a rare disease. So as you're seeking care and support for them, it's not always about the medications. It's about that total person and thinking really holistically about the individual and their care teams that are impacted by those conditions. So the external community we were serving really drove me and introduced me to something that I've stayed with, and it brings great passion to try to find ways to support individuals in our western society, but also looking at low middle income countries and helping facilitate diagnosis to treatment to, again, that whole supportive care and largely from the internal teams within the organizations I've worked with has just is been tremendously rewarding and also equally challenging. It's beautiful to see progress. I mentioned diagnosis and. One of the areas I worked in initially was in the lysosomal storage disease area. And it's the age-old question on diagnosis. Do you facilitate newborn screening, for example, so when your child is born, you have a heel prick done and you can do a series of tests depending on the state you live in, and in some countries in Europe it's also provided. But if there's not a therapy, is it okay to do that type of diagnosis support. And so that challenge, you know, in seeing the policy evolve on a state by state basis. When I began in the rare disease space and MPS Type Two Hunter Syndrome, it's a condition that affects mostly boys and a very small part of our population. We knew we could do newborn screening and there was a therapy available, but it wasn't only realized until a few years ago to introduce newborn screening to help those families at the point of birth to know if their child was affected, and therefore start a different trajectory on how they planned for care for them and plan for if there was a medication or other supportive tools and resources available for them. So it's been extremely dynamic to see how things have evolved. And then now as you see medical and pharma medical technology advance as well into gene therapies. You're seeing news about gene therapy and it's a one time treatment and then the individual hopefully will not have be re redos in their lifetime. Along with that come challenges on that diagnosis piece to make sure they're eligible for the gene therapy. So again, through the device and technology sector, it plays a key role. In addition to the supportive care that goes on for some of these really severe conditions, people have some pretty dynamic needs and it's great to see how things are progressing, but it's still as equally as frustrating, whether you're on the manufacturer side or the family side, to see things be kind of slow sometimes. [00:06:15] Lindsey Dinneen: Yeah, of course. And you're dealing with a specific situation where many times-- please correct me if I'm wrong-- but it seems like many times there's these kinds of studies and conditions are not funded very well in terms of finding solutions to the problem. So how is that something that you, well, first of all, of course we're in a very interesting season of life right now. So how are you seeing funding evolve over the years for these different diseases that are a little bit more rare, and what can we all do in terms of even just awareness and understanding? [00:06:51] Sara Aswegan: Yeah, so that's a huge question. We could probably have about five conversations on this just to scratch the surface, Lindsey. I think if I reflect on the question on what we've seen around funding, I mean there are some wonderful, supportive grants available for the brilliant scientists we have around the world that have a curiosity. So making sure we can facilitate that ongoing academic environment to explore and test the hypothesis. And one of the things that you see coming along, and it's not really around-- I won't think about funding as just pure financial-- but it's the funding of the smarts that go around the table. You see a lot more collaboration amongst academia, industry governments coming together to help build and scale so that there's an awareness and understanding of a condition. I mean, a pediatrician could go through their entire career and never see a boy with Hunter Syndrome. It's just that rare. At the same time, and on the converse of that, if you're working in an industry where you do have access to more funds, the introduction of AI and looking at how we look at drug targeting, drug target selection, genetics and precision medicine have come along quite leaps and bounds in the last several years, but we're still not quite there. But you're seeing advancements with the different cell and gene therapies, having that precision medicine as an option. It's coming forward. The challenge is the size of studies are normally very small because the population is small. So thinking about patient recruitment, how can we help facilitate better identification of individuals that may be out there and not have received diagnosis because of the rarity of the condition? So looking at technology and advancement of integrated electronic health records up to and including, how do we look at the trial designs? And how do manufacturers, academics, industry, and agencies work together to think a little differently around even designing clinical endpoints for the studies that really are meaningful, that will make a difference. And how do you balance that, right? Correct risk benefit conversation, in the spirit of doing no harm. But if there's one chance and there's something available, how do you do that? And coming all the way downstream. If you think about where the organizations have advanced their thinking, their approach, and put funds behind, it's also that ongoing care of the individuals. If you look at the upstream, the types of tests that are available. It could be cancer, it could be the area I am so passionate about in genetic disorders, but it can also be thinking about the workflows that come into play in helping facilitate consistency of care across state borders, across country borders. It's a key piece that are really advancing in real time, but we're still trying to overcome the hurdles that are real. And that's things around data privacy. How do we navigate that in a really meaningful way with the right ethics and integrity. If we think about the regulators, this isn't a huge anti-infective or cardiac study that's ongoing, that there are gonna be tens of thousands of people. So how can we think a little bit differently on advancing the care. In the area I'm working in, Lindsey, especially with some of these individuals that are kids, if they don't get access to care by a certain age point, their window of treatment has closed. And so what could we do to help facilitate earlier diagnosis and then that advanced care. And so I think we can see a lot of really good intentions, and I think the most beautiful thing is even the collective gathering of different patient organizations that have a shared interest of a disease coming together and also helping raise research funds to help support the scientists that have a hypothesis on something that may really make a difference and may matter. [00:10:21] Lindsey Dinneen: Yeah. Yeah. Okay, so, there has been so much innovation in the last few years-- of course, even before that, but it seems to be extremely exciting in the last few years-- especially things like CRISPR and all sorts of new technologies emerging. What are some of the exciting trends that you're seeing in this space specifically that give you hope as you continue to look forward and look for solutions? [00:10:45] Sara Aswegan: I think for me, I mentioned, I touched on it lightly. I think it's that collective, that collaboration and the openness now. The FDA has advanced the way that they think and engage with agencies as well as industry partners. And so what I mean by that, Lindsey, is they're not just engaging with the scientists or with the manufacturers, the drug developers. They're also bringing patients in. And so that collaborative environment, they're even beginning conversations when there's discussion on clinical trial design to understand what really matters. Is it a six minute walk test or is it something around real behavioral or other abilities that can be learned and retained over time that help benefit the quality of life? If you're not gonna be able to cure something, what's really important at that patient front to help facilitate something meaningful. So I think that type of conversation also with the agencies looking at, there was an amazing session held in Europe recently in the mucopolysaccharidosis or the lysosomal storage disease area, looking at advancements of science and saying, can we look at biomarkers alone and create that relationship and understanding there is a clinically meaningful impact if we can address this biomarker. And so, companies like Ultragenyx have really pushed to have that conversation and dialogue and have a drug filed now that's under review based on biomarker endpoints alone, where five years ago, you would never have imagined that being possible. [00:12:12] Lindsey Dinneen: Yeah. Yeah. You touched on something that I would really love to explore a little bit deeper, and that is, when there's a situation that right now we don't have a cure for this disease-- and, you know, obviously we're still working towards it-- but if we don't have a cure, but we are trying to improve the quality of life, how do you balance that in your specific field in terms of: obviously you want the patients to live the best quality of life that they can while balancing so many other, and I don't mean this in a callous way at all, just from a practical perspective, balancing all of these other considerations and things that are also desiring funding and all those competing priorities. So how do you balance that? How, how does that come into play? [00:12:57] Sara Aswegan: So that's a big one. It's a tough one. And I'll oversimplify it and just say data. And what I mean by that, Lindsey is really looking at, with the technology at our fingertips, regardless of the geography you're living in, there's a lot of meaningful information that can be captured. And it's not, again, around one aspect of a disease, but it's the totality of health. So really looking at what could be possible in capturing, is it around energy levels, activity levels. And you'll see that oftentimes in play with the gene therapy, for example, when it's administered, you may have up to 15 years of follow up that you're capturing specific data points. But even in advance of a drug approval, and an area I am also equally passionate about, is access to unlicensed medicines for individuals that can't travel to a clinical trial site and could benefit from an investigational therapy, how do we do that with the right balance in place? And part of that is data and having the willingness of a participant or family member to be so consented in and participating in the study for their child to share that data and share that real world data or real world evidence so that you can measure back and show what impact that drug or treatment or intervention has been having on the individual. So I think it's around that and figuring out how we can overcome some of the complexities and challenges that are real. Not everyone has electronic health records. There's still lots of paper-based offices out there. But in the meantime, there's a lot of advancements in technology. So how do you appropriately use that, that it's also not overburdensome for the individual, for the family as well, that you're doing what really matters and measuring back and having the right conversations with the individuals affected, the investigators, the clinicians, but then the regulators, and going back and sharing why this can be something to help substantiate. It's not your standard phase 1, 2, 3 clinical trial design. That's, yes, there's rigor, but it's a different way of looking at using data to help us advance our understanding of a disease and what's needed by the individual affected. [00:14:53] Lindsey Dinneen: Yeah. So, so when you're speaking with these families and or-- well, first of all, let me actually back up. Do you have direct communication with some of these families and patients that you're working with? [00:15:04] Sara Aswegan: Yes. [00:15:05] Lindsey Dinneen: Yeah. And so when that happens, how. How is it for you? I mean, this is such a challenging area that you have devoted your life to and to, and I'm so impressed with that. And, you're doing the work that's helping save lives and make a difference. But that must be really challenging from a personal level to have these difficult conversations. So how do you balance that as a practitioner and somebody who's desiring to help, but you also have this real life compassion and human being that you're trying to help? [00:15:38] Sara Aswegan: It's tough and it's tremendously rewarding. At the same time, I have so many patient stories I can share with you of meeting them and meeting 'em where they are. I made a trip to Sao Paulo, Brazil once, Lindsey, and met a family that were living in the favelas there, and their aim was to help raise awareness for Hunter's Syndrome because their son had been undiagnosed. They knew something was wrong. He was nonverbal. He had some physical presentation that you could understand. There was something going on, but the technology wasn't there for them. The access to the care center wasn't there for them to get a diagnosis. They were taking buses for hours to different clinics to figure out what's wrong with our son. And he finally received a diagnosis of Hunter Syndrome and they wanted to share the photos because kids with Hunter Syndrome do have some different dysmorphism. So there's something that's strange. They have a bossy forehead, or their bridge of their nose is a little different. Their bellies might be a little bit bigger. So if you start looking at all of these different clues and putting it together, you might suspect and go-- there's other things going on, for sure. So I'm oversimplifying this. However, getting a diagnosis for him by just raising awareness to other families of the physical presentation and what their experience was extremely meaningful for them. And on balance, a family in Florida that I met and their son was diagnosed at age 18 months because their grandmother had seen a program on Mystery Diagnosis and said, "That sounds like my grandson." And so creating the conversation and meeting people where they are is really important because you may have some individuals that are very aware of how drugs are developed and all of the rigor that goes through that to then others that just they don't understand that some drugs are intended for a specific indication, specific population, and helping explain why their child may not be eligible for a particular study. It's tough, and that's not my responsibility, but the clinical teams and the clinicians that are having those conversations. So it's listening and really coming with a open heart and mind and having empathy to help figure out how can you educate. It's even moving into gene therapy. What does gene therapy actually mean? What are the risks? I'm afraid this sounds like it's something so futuristic. What will this mean for my son or daughter in 10 years from now? And, we may not have all of the answers, but you know, science has advanced and it's that risk benefit that you have to exercise. But really it's that coming with compassion and a listening ear and understanding and being honest. And if I can't help, maybe there's someone else that can help or there's a, did you know, there's a clinic here or a center there and helping that network stay connected and thrive is really important. And also being their voice, Lindsey, I mean, we can, we have an opportunity on our pharma, biomedtech side of the world that we can share what we've observed and try to apply that as we come to work every day and think about that family we met in Brazil or in Boston or in Florida or in, you know, Frankfurt, and whatever they may be experiencing. So it's being their advocate in other areas as well. [00:18:34] Lindsey Dinneen: Yeah, exactly. So with what you deal with, I am wondering what kinds of misconceptions or myths do you often encounter that are interesting and yet you would prefer to correct so that those of us in the general population are more informed? [00:18:52] Sara Aswegan: That's a good one. So I think having worked in the rare disease space, one of the biggest scrutinies there, there's on two sides of the coin. One is around diagnosis and why we can't do more around diagnosis. And sometimes the science is just not there yet. So again, to some of these experiences, like the story of the family in Brazil, it may not be about a blood test. It may be about a physical appearance and helping people piece things together. I think on the other end is at the point of delivery of the diagnosis and then if there is a treatment or intervention that can be taken, and not everyone has the same principle in their heart. There are companies that are motivated for different reasons, but certainly the big topic is are around drug prices, whether it's a gene therapy or a chronic lifetime medication, of how do we navigate that and how do we navigate that in a better way? And I think we have to start looking as an industry, as a community of people, of how do we address that? The cost of doing a clinical trial is tremendous. It's hugely expensive. Does it warrant though huge price tags on drugs forever in perpetuity? What's that right balance? And I think having a level of social responsibility and looking at alternatives. And so imagine if we could reduce the time for clinical studies for requirements because we're able to look at other data. Things like the biomarker approach and the follow on real world data that could be captured, could that help us in the total overall offering and the cost to the overall health system? Maybe. I think that as an industry, every company operates with different principles and wanting to do best for the patient community. Some are more profit driven than others, and so that's a reality, and it's one that I get so often at dinners with friends or in personal conversations, professional conversations, and it's a tough one. At the same time, a study of 60 individuals could be double digit millions of dollars. Just the cost of facilitating the study, the production costs of some of these highly technical compounds of different therapies also becomes a factor. So you have to put all these pieces together and really explore what's driving that. [00:20:57] Lindsey Dinneen: Yeah, of course. And yes, I'm sure that's a really difficult conversation to have too, when you're especially working directly with patients and trying to explain all of that and that's a lot. That's a challenge. [00:21:10] Sara Aswegan: Yeah. Yeah. [00:21:11] Lindsey Dinneen: But on the flip side, you know, of course the work that you do makes a huge impact, and I'm wondering if there are any stories that come to mind that just really reinforced to you, "You know what? I am in the right place at the right time, in the right industry." [00:21:25] Sara Aswegan: Absolutely. And I think it goes to, I touched on it very briefly, and there are people that aren't living in near major cities, near major medical centers, and that should not make them obsolete from receiving the best care. And there are two things that have happened and partly because of the pandemic, but also partly because of the willingness to educate and have that connected community amongst clinicians, is around that access to unlicensed medicine and finding pathways that it's not just because a doctor says your son or daughter needs this medication. I'm going to reach out to the manufacturer to see if I can get access because they're not near a clinical trial site or they don't wanna participate, or they're unable to participate in a study. But finding means to do that. And there have been some really creative ways that clinicians have been able to do that, of setting up qualified treatment centers where the individual can go to receive the treatment and then that continuity of care is provided then over the life of their disease. It's something that's become real and meaningful, and you would be shocked at the number of individuals around the world that are receiving access to medicines that normally might have only 10 years ago been available if you were living in the Western Europe or the United States because studies weren't conducted in their country and so there's no pathway for access that is all changing. Those dynamics are changing. It takes a team of people, though. It takes regulators, it takes lawmakers, it takes industry. It takes our logistics teams to be sure if something's stored at cold chain, that that product is delivered in the right context at the right time, just in time for that patient to receive it. So it's a complex challenge, but it's one that we've seen serve individuals in a really meaningful way. And without that, they wouldn't have, they wouldn't have another option. [00:23:11] Lindsey Dinneen: Yeah. So having that impact and just being able to reinforce in those moments of maybe when it's especially difficult or you're especially frustrated like, "Oh my gosh, I wish I could help X, Y, and Z," at least you can look back and go, "Yes, but look at all this that we are doing." [00:23:26] Sara Aswegan: You know, Lindsey, also it's that education piece and being curious and asking questions. The scientific community and one of the lead leaders in the NPS community is in North Carolina, Joe Munzer. Dr. Joe Munzer, he's brilliant. And one of the initiatives that we started was something called a masterclass. And so with Dr. Munzer and seven or eight other clinicians from around the world, we literally went on an educational program around the world. And some of the individuals that had just come out of their postgraduate work, pediatric geneticists or neurologists meeting the number one or two people that know this space so well, being mentored by them. And now those individuals are facilitating their class, the same type of class in their local language to their local communities and creating that level of education and awareness. I mean, it's just to see that real impact over time. I actually get goosebumps just thinking back on the impact that has had. And you've got a community of clinicians that they're, I mean, there's a lot of needs still to study medical genetics. And so hopefully we have individuals that are scientifically interested and will continue that that journey so that they can be the next teachers across borders. That makes the difference. [00:24:37] Lindsey Dinneen: Yeah. Absolutely. Wow. Yeah. Thank you for sharing that. I was also getting goosebumps just listening to it because that's incredible ripple effect that you had and continue to have. That's amazing. [00:24:47] Sara Aswegan: Yeah. Yeah. [00:24:47] Lindsey Dinneen: Yeah. Oh man. Okay. Well, I could talk about this for a long time, but pivoting the conversation a little bit, just for fun. Imagine that you were to be offered a million dollars to teach masterclass on anything you want. It can be within your industry, but doesn't have to be. What would you choose to teach? [00:25:05] Sara Aswegan: Wow. That is a great question, Lindsey. A masterclass-- a million dollars-- a masterclass on anything I would want. I would be drawn to some of the advancements we're seeing in gene therapies, but I think that would be, I wanna try to serve a broader population. Do you know? I think it's, I think if I could look, I would do something around looking back on some of these, if you will use cases and best practices, to share those learnings, just because we know the impact that it will have and has had and continues to have. And not just on the scientific community, but it ripples down into the patient communities of asking that question of "what can be possible, how can we together." Instead of " no," it's actually, "yes and" or "no and" we hear something else, another construct. And really breaking it down to really enforce what I've talked about on several moments during our conversation today is it can't just be the manufacturer, the, or the developer. It can't just be academia. It can't just be health authorities or regulators. It's a collective community and it has to include that patient within that conversation to help for that learning and advancement and understanding. And so I think it's something around that, the best practices, use cases, and really things that made a difference. Meeting people where they are of a good understanding of the science, not good understanding of the science, that crosses all levels. Drug development overall. The total continuity of care for my individual affected. It's not just about a drug, but it's about assistive devices or other tools that they can have a better life. And so being really thoughtful about that I think would be something that would be really amazing. That it's actually captured and taught back. [00:26:47] Lindsey Dinneen: Yeah, absolutely. That would be a fantastic masterclass. All right, and then how do you wish to be remembered after you leave this world? [00:26:56] Sara Aswegan: Well, at some point I know my husband will admit I have the best sense of humor. [00:27:01] Lindsey Dinneen: Yes. [00:27:02] Sara Aswegan: I think for me, Lindsey, I really would hope that people would say an open heart, a generous heart, and just a connector of people, personally, professionally. It takes two seconds to be kind and open and nobody has all the answers. So help people connect with others and be willing to say, "How can I help?" [00:27:20] Lindsey Dinneen: Yeah, absolutely. Yeah. And then final question, is one thing that makes you smile every time you see or think about it? [00:27:31] Sara Aswegan: I just came in from my garden and I have to say, seeing my advancement of fostering my garden and I've got things blooming now. There is hope. [00:27:40] Lindsey Dinneen: I love that. I feel that way every time I somehow succeed in keeping a plant alive. [00:27:45] Sara Aswegan: There is hope. It's really around the simple things, right? That's it. [00:27:49] Lindsey Dinneen: Yeah, absolutely. Now, for any of our listeners who are excited to get to know about you and your work a little bit more, can you just share briefly what is it that you do right now to help companies succeed and how can people get in touch with you? [00:28:02] Sara Aswegan: Thanks, Lindsey. So I am currently doing some advisory board work for a couple of consultancies as well as helping some small and mid-sized biotechs figure out their pathway and how they go to market. How do they facilitate access to unlicensed medicines? I'm passionate about the rare space, so I'm serving also on a couple of special projects on getting drugs and diagnostics into low middle income countries. And it's something I'm very passionate about and I've got a great network of people. So if I can't help, I'm always happy to say, "Not me, however, I know someone you should talk to." And to get in touch, it's not easy to spell, but it's www.saraaswegan.com. And again, if I can't help, I might know someone who can. And I think it's just, it's really good to share our knowledge and experience and really make a difference however we can. [00:28:47] Lindsey Dinneen: Yeah. Absolutely. Well, thank you, Sara. This has been absolutely incredible to learn from you, to hear about your story. So thank you for sharing and being open. I really appreciate that. And my goodness, I just wish you the most continued success as you work change lives for a better world. [00:29:03] Sara Aswegan: Thanks Lindsey, and thanks for everything you're doing. Really, hats off. Thanks a million. [00:29:07] Lindsey Dinneen: Of course, and have the best rest of your day. And thanks also to our listeners for tuning in. If you're feeling as inspired as I am right now, I'd love it if you shared this episode with a colleague or two and we'll catch you next time. [00:29:22] Ben Trombold: The Leading Difference is brought to you by Velentium. Velentium is a full-service CDMO with 100% in-house capability to design, develop, and manufacture medical devices from class two wearables to class three active implantable medical devices. Velentium specializes in active implantables, leads, programmers, and accessories across a wide range of indications, such as neuromodulation, deep brain stimulation, cardiac management, and diabetes management. Velentium's core competencies include electrical, firmware, and mechanical design, mobile apps, embedded cybersecurity, human factors and usability, automated test systems, systems engineering, and contract manufacturing. Velentium works with clients worldwide, from startups seeking funding to established Fortune 100 companies. Visit velentium.com to explore your next step in medical device development.

Join Jay Gunkelman, QEEGD (the man who has analyzed over 500,000 brain scans), Dr. Mari Swingle (author of i-Minds), and host Pete Jansons for another engaging NeuroNoodle Neurofeedback Podcast episode discussing neuroscience, psychology, mental health, and brain training.✅ Autism & EEG: Jay and Dr. Mari explore autism's rise, EEG patterns, and why autism isn't “one thing” but a spectrum with genetic clusters and neurophysiological signatures.✅ Dehydration & Mental Health: How hydration, cortisol, and electrolyte balance impact EEG readings, stress, and mental performance.✅ Neurofeedback Setup Essentials: From sleep, hydration, and no gum to avoiding “wet dog” hair — the panel shares real-world stories of EEG prep gone wrong (and right).✅ Additional Topics:

As the gene editing field kept growing, so did the dangers. Back in 2018, Jennifer Doudna received an email from a Chinese scientist claiming that he had genetically edited two twin babies. The news reverberated across the world and made Doudna and her colleagues urgently consider the implications of what their discovery could mean for humanity. Walter Isaacson sits down with Evan and tells him why the field has always been ripe with ethical questions, and how the COVID-19 pandemic pushed researchers to recalibrate their priorities.See omnystudio.com/listener for privacy information.

Guest: Alexis Leonard CRISPR technology, while relatively new, has shown potential in treating patients with sickle cell disease by increasing fetal hemoglobin. Though this gene therapy comes with safety considerations, refinements and advancements in CRISPR technology can offer new management options for sickle cell disease patients. Learn about the history of CRISPR as a sickle cell disease treatment and the future of this strategy with Dr. Alexis Leonard, who works in the Department of Hematology at St. Jude's Hospital in Memphis, Tennessee.

Explore the transformative impact of artificial intelligence and automation on the produce and floral industries with host Vonnie Estes and guest Joe Don Zetzsche. With insights from Joe's extensive experience, the episode delves into AI's role in reshaping retail, revolutionizing floriculture breeding, and redefining supply chains. Discover strategies for growers and retailers to adapt and thrive amid rapid technological advancements. As AI models grow exponentially, understand how embracing these changes can unlock abundance and sustainability in everyday business practices.Key Takeaways• Exponential Growth Understanding: Joe explains the concept of exponential tech growth and its implications on human understanding and industry evolution.• AI in Retail: AI is revolutionizing retail operations, with companies like Amazon and Walmart leading through data integration and automation.• Impact on Medium and Small Retailers: Smaller retailers may face challenges without strategic adoption of AI technologies, potentially paying other companies to fill those gaps.• AI's Role in Floriculture: AI's integration in breeding processes is leading to more resilient and higher-performing floral varieties, highlighting future potentials for genomics and CRISPR technologies.• Cultural and Economic Shifts: Consumer acceptance of AI-driven services, like delivery of perishables, signals a cultural shift towards automation-enhanced convenience.Guest Resources• Joe Don Zetzsche: Currently supporting the floral and retail industries through consulting.• International Fresh Produce Association (IFPA): Fresh ProduceFor more insights into how AI and technology are reshaping industries, listen to the full episode and stay tuned to “Fresh Takes on Tech” for more thought-provoking discussions.Show LinksInternational Fresh Produce Association - https://www.freshproduce.com/Fresh Takes on Tech - https://www.freshproduce.com/resources/technology/takes-on-tech-podcast/Facebook - https://www.facebook.com/InternationalFreshProduceAssociation/Twitter - https://twitter.com/IntFreshProduce/LinkedIn - https://www.linkedin.com/company/international-fresh-produce-association/Instagram - https://www.instagram.com/intlfreshproduceassn/

We are playing God | Slavoj Žižek and Yuval Noah Harari on CRISPR, AI, and the future of humanity https://youtu.be/V66hlLruZTU?si=MdlJRiceXyWigZ0R have you ever seen a parasailing spider?  https://youtube.com/shorts/qjUAhaRdVb4?si=YMC2EVKTw2jP3CHU How India's unplanned hydropower dams and tunnels are disrupting Himalayan landscapes https://theconversation.com/how-indias-unplanned-hydropower-dams-and-tunnels-are-disrupting-himalayan-landscapes-261956 The Ganges River is drying faster than ever – here's what it means for the ... Read more The post quando perdemos a curiosidade? aranhas que voam! o risco de brincarmos de Deus appeared first on radinho de pilha.

2/4: HEADLINE: High-Profile Corruption and Genetic Manipulation: The Cases of Lieber and He Jiankui GUEST NAME: Brandon Weichert 50 WORD SUMMARY: Brandon Weichert details how the Thousand Talents Program corrupted US scientists like Harvard's Charles Lieber, who shared military-grade nanotech research with China. The discussion pivots to the dual-use threat of CRISPR, an American genetic tool used by He Jiankui to modify unborn twins, potentially causing unintended brain augmentations. Biohacked: China's Race to Control Life. Brandon J. Weichert  (Author) 1968 MAO AND LIN

TWiV explains experiments to create genetically modified chickens that are resistant to avian influenza infection, and discovery of combination antiviral therapy for HTLV-1 infection. Hosts: Vincent Racaniello, Alan Dove, and Rich Condit Subscribe (free): Apple Podcasts, RSS, email Become a patron of TWiV! Links for this episode Support science education at MicrobeTV Creating avian influenza virus resistant chickens (Nat Comm) Antiretroviral therapy and apoptosis inhibition for HTLV-1 (Cell) HTLV-1 infection (Cleveland Clinic) Letters read on TWiV 1257 Timestamps by Jolene Ramsey. Thanks! Weekly Picks Rich – Chagas Disease, an Endemic Disease in the United States Alan – Archive of molecular biology artifacts ends its long, strange trip at a museum Vincent – The World's Oceans Are Hurtling Toward Breaking Point Intro music is by Ronald Jenkees Send your virology questions and comments to twiv@microbe.tv Content in this podcast should not be construed as medical advice.

It's a dystopian new spin on spirituality in the digital age – and one that just might be poised to change the face of religion itself. Pastor Gene Pensiero Find audio, video, and text of hundreds of other prophecy updates at: https://calvaryhanford.com/prophecy Read along with us at https://calvaryhanford.substack.com Follow us on YouTube at https://youtube.com/calvaryhanford — […]

This week, we’re bringing you the first episode of Season 3 of the podcast ON CRISPR. Walter Isaacson — the bestselling biographer behind Musk, Einstein and Steve Jobs – and journalist Evan Ratliff (Shell Game, Mastermind, Longform) take a behind-the-scenes look at the story of Jennifer Doudna, one of the scientific pioneers behind the gene editing software, CRISPR. In this episode, Evan sits down with Walter Isaacson to discuss Doudna’s upbringing, the history of DNA’s discovery and gene editing, and Baby KJ, a CRISPR patient who represents a milestone for both researchers and patients.See omnystudio.com/listener for privacy information.

Jennifer Doudna thought she had won the race. She thought she had beaten out all scientific competitors when she and her co-author had shocked the world with their groundbreaking technology for gene editing. But turned out, the race had just gotten fiercer. Walter Isaacson sits down with Evan to talk about how one of the most cutthroat scientific competitions in biotech got started around one goal — making CRISPR work for humans, and getting the credit for it.See omnystudio.com/listener for privacy information.

In this episode of IDEA Collider, we are joined by Alex Telford, a biotech founder, writer, and thinker based in the San Francisco Bay Area. As the co-founder of Convoke Bio, Alex discusses his journey from studying biochemistry at UCL to founding a company that develops software tools for streamlining biopharmaceutical workflows.The conversation dives into the impact of AI and language models on the biotech industry, addressing inefficiencies in drug development, and exploring the potential of synthetic biology and personalized medicine. The discussion also touches on the future of drug discovery, China's role in biotech, and the challenges of understanding neuroscience and consciousness. Don't miss this insightful discussion on the future of biopharma innovation! 00:00 Welcome to Idea Collider00:04 Introducing Alex Telford01:59 Alex's Journey from UCL to Convoke Bio05:29 The Mission and Work of Convoke Bio07:57 Challenges in Pharma Decision Making14:05 The Role of AI in Pharma18:26 Knowledge Management and AI27:58 Staying Updated in the Fast-Moving AI Field30:25 AI's Impact on Industry Economics31:38 AI in Clinical Trials and Drug Development35:56 China's Role in Drug Discovery39:24 Neuroscience and AI: Blurring the Lines46:05 Future Predictions in Pharma51:20 Addressing Cognitive Bias in Pharma53:13 Concluding Thoughts and Future Directions Keep up with Alex Telford;LinkedIn: https://www.linkedin.com/in/alexander-telford/Website: atelfo.github.ioX: https://twitter.com/atelfoSubstack: atelfo.substack.com Follow Mike Rea On;Website: https://www.ideapharma.com/X: https://x.com/ideapharmaLinkedIn: https://www.linkedin.com/in/bigidea/ Listen to more fantastic podcast episodes: https://podcast.ideapharma.com/

We discuss the sketchy "science by press release" of Colossal Biosciences and the controversies lurking in the history of its lead scientist. Have they resurrected dire wolves? No. Definitely not. If only overblown celebrity endorsed hype was the only problem…Did they make a Dire Wolf? (Spoiler: NOT EVEN REMOTELY CLOSE)George Church's explanation of Epstein tiesJames Arthur Ray - Guru of Death?Tony Robbins (more from Quora and Reddit)Peter Jackson and the MoaGeorge R. R. Martin and the Dire WolfFor a more… salacious take on this, check out the 2-part "Behind the Bastards" coverage of this topic. Part 1 and Part 2.--- on a more positive note ---What is CRISPR?Become a supporter of this podcast: https://www.spreaker.com/podcast/monstertalk--6267523/support.Some product links may be affiliated with Amazon revenue sharing.

We're fascinated by the microbiome — and for good reason. But how do we protect this invisible ecosystem that plays such a vital role in our health?From engineering live, programmable therapeutics that disarm dangerous gut pathogens to creating a global “doomsday vault” to safeguard the diversity of human gut microbes, we dive deep into the cutting-edge science shaping the future of microbiome research.Show notes1. Ronda, C., Perdue, T., Schwanz, L. et al. Precise virulence inactivation using a CRISPR-associated transposase for combating Enterobacteriaceae gut pathogens. Nat. Biomed. Eng (2025). https://doi.org/10.1038/s41551-025-01453-12. 2. Dominguez-Bello, M.G., Steiger, D., Fankhauser, M. et al. The microbiota vault initiative: safeguarding Earth's microbial heritage for future generations. Nat Commun 16, 5373 (2025). https://doi.org/10.1038/s41467-025-61008-5

Back in the 1990s, a young microbiologist in Alicante, Spain became obsessed with a strange pattern he observed in the genes of tiny organisms — a series of inexplicable clusters. And he wasn’t alone. All around the world, a network of scientists were growing curious as to what these genetic knots could be and all of their potential functions. Their curiosity would prove to be the foundation for a history altering discovery: the ability to edit our genetic code. See omnystudio.com/listener for privacy information.

00:45 Attributing extreme heat events to major energy producersMajor energy producers increased the likelihood and intensity of heatwaves, according to research published in Nature. Using data from an international disaster database, a team developed a methodology to investigate how much anthropogenic climate change had influenced heatwaves. They conclude that many of these events would have been “virtually impossible” without climate change, and that nearly a quarter of the heatwaves recorded from 2000 to 2023 can be directly linked to the greenhouse-gas emissions from individual energy giants.Research Article: Juvé et al.News and Views Forum: Heatwaves linked to emissions of individual fossil-fuel and cement producersNews: Dozens of heatwaves linked to carbon emissions from specific companies10:47 Research HighlightsHow shifting coastal tides may have spurred the rise of the world's oldest civilization — plus, the liquid crystal lenses that can refocus in a flash.Research Highlight: Changing tides ushered in the world's first civilizationResearch Highlight: Liquid-crystal specs refocus with the push of a button12:40 The growing resistance to the US war on scienceScience in the United States is facing an increasing crisis, in the face of swinging cuts and President Donald Trump's ongoing attack on anything with a connection to diversity, equity and inclusion. In the face of this crisis, many researchers are fighting back — we hear about some of their efforts, and what they think about their chances of success.News Feature: Scientists take on Trump: the researchers fighting back27:28 Briefing ChatHow CRISPR-edited pancreas cells could offer new hope for those with type 1 diabetes, and what brain scans reveal about how we process colour.Nature: Hope for diabetes: CRISPR-edited cells pump out insulin in a person — and evade immune detectionNature: My blue is your blue: different people's brains process colours in the same waySubscribe to Nature Briefing, an unmissable daily round-up of science news, opinion and analysis free in your inbox every weekday. Hosted on Acast. See acast.com/privacy for more information.

Football Team Valuations Sexy is back - Retail What winning the Powerball Jackpot means A little 1,000,000 revision... PLUS we are now on Spotify and Amazon Music/Podcasts! Click HERE for Show Notes and Links DHUnplugged is now streaming live - with listener chat. Click on link on the right sidebar. Love the Show? Then how about a Donation? Follow John C. Dvorak on Twitter Follow Andrew Horowitz on Twitter Warm-Up - Stagflation - as payrolls drop - People in glass houses ....Stupid Politics - We are still here - which means we did not win the Powerball Jackpot - They say it will never happen - Ban on stock ownership for Congress Markets - CRISPR Chocolates? - Tech - again the driver - Sexy is back - Retail - Take in stride - on 900k less workers - ORACLE!!!!!! Powerball Jackpot - $1.8 Billion - Two winners - Texas and Missouri - Each winning ticket holder can choose either an annuitized prize of $893.5 million or a lump sum payment of $410.3 million – both before taxes. - Additionally, two lucky tickets sold in Kansas and Texas won a $2 million prize and 18 tickets sold across 13 states won $1 million. - Back to just $20 million now... - The odds of winning were 1 in 292.2 million, according to the Multi-State Lottery Association, which oversees the game. Glass Houses - Pulte - Accuses Fed's Cook and with simple accusations Trump looking to Fire ... - Close relatives of the federal official who has accused a Federal Reserve governor of improperly claiming primary residence on two properties have declared the same status on two homes in two different states, public records show. - Mark and Julie Pulte, the father and stepmother of Bill Pulte, President Donald Trump's appointee as director of the Federal Housing Finance Agency, since 2020 have claimed so-called “homestead exemptions” for residences in wealthy neighborhoods in both Michigan and Florida, according to the records. The exemption is meant to give a discount to homeowners on taxes for properties they use as their primary residence. - Local tax officials in both states told Reuters that claiming more than one home as a primary residence isn't generally allowed in their jurisdictions and could be punishable by fines or back taxes. - After Reuters contacted tax officials in Bloomfield Township, Michigan, to inquire about the dual claims, Darrin Kraatz, director of assessing, on Thursday said the township “as of today” would revoke the exemption on the Pultes' residence there. Beat Your Ass - Seems at a recent dinner- Pulte got under Scott Bessent's skin and bessent was pissed - F You - I am going to beat your ass - punch you in the F'n mouth for bad talking me to president Trump - Class act these children Chocolate Editing - Candy maker Mars said Wednesday it has partnered with biotech company Pairwise to speed up the development of more resilient cocoa using CRISPR-based gene editing technology. - CRISPR technology is a gene-editing tool that makes changes to DNA and can be used in farming. - The goal is to create cacao plants that can better withstand disease, heat and other climate-related stresses that can put global chocolate supply at risk. ---- Public Service: The main difference between cocoa and cacao: cacao is minimally processed and remains largely raw and nutrient-dense, while cocoa is made from roasted cacao beans that have been processed at high temperatures. This heat and processing affect cacao's nutrient profile and flavor, making cacao powder more bitter and richer in nutrients, and cocoa powder milder and more suitable for baking. GOOGLE for the win - Google shares popped 8% on Wednesday last week as investors celebrated what they viewed as minimal consequences from a historic defeat last year in the landmark antitrust case. - Last year, Google was found to hold an illegal monopoly in its core market of internet search. - U.S.

Earlier this year, when the world learned the news of baby KJ successfully undergoing the first personalized genetic treatment, it represented a milestone for researchers and patients. But behind this scientific feat there’s the story of the technology that made it possible, CRISPR, and one of the key pioneers behind it — Jennifer Doudna. Evan sits down with Walter Isaacson to understand how Doudna’s upbringing in Hilo, Hawaii influenced her trajectory as a gene editing scientist. And how the history of gene editing might have started with understanding DNA, but soon after, it became clear the real secret lay with its underrated sibling molecule, RNA.See omnystudio.com/listener for privacy information.

In this special episode, host Jeremy Schrand sits down with Jill Brinck, Executive Director of CancerFree KIDS, and Dr. Genevieve Kendall, a CancerFree KIDS grant recipient and pediatric cancer researcher at Baylor College of Medicine. Together, they explore the power of early-stage research funding, the challenges and breakthroughs in treating childhood cancers, and the inspiring mission behind CancerFree KIDS. Dr. Kendall shares insights into her lab's work on fusion-driven rhabdomyosarcoma and how innovative models like transgenic zebrafish are helping uncover new therapeutic targets. Whether you're a parent, a scientist, or someone passionate about making a difference, this episode offers a compelling look at how collaboration and curiosity are driving real change in pediatric oncology. Learn more - CancerFree KIDS home page Learn more about Dr Kendall's research - Kendall Lab | Nationwide Children's Hospital Learn more about CTI - CTI - CRO Specializing In Clinical Research And Consulting  02:03 Jill Brink shares her personal and professional journey that led her to become Executive Director of CancerFree KIDS.  04:02 Why funding early-stage, high-risk research is essential for pediatric cancer, highlighting the lack of profitability and federal support in this space. 05:46 Securing funding for early-stage research presents major challenges, including the need for collaboration between scientists and business leaders.  07:06 How CancerFree KIDS selects research projects, outlining the role of their Scientific Advisory Council and the grant scoring process. 09:26 Success stories driven by CancerFree KIDS funding, including early support for clinical trials and advancements in flash proton therapy. 11:22 Dr. Genevieve Kendall explains the nature of fusion-driven rhabdomyosarcoma and why its aggressive behavior and lack of targeted therapies make it difficult to treat. 13:51 How the CancerFree KIDS grant supported a new partnership and provided seed funding to test a promising research idea. 14:50 The significance of identifying HAS3 as a novel target and how it opens new possibilities for treating rhabdomyosarcoma. 16:35 Dr. Kendall describes the role of transgenic zebrafish in her research and how they help uncover therapeutic targets through comparative oncology. 19:33 Both guests share what excites them most about the future of pediatric cancer research, including innovations in CRISPR and immunotherapy. 22:32 How CancerFree KIDS measures the long-term impact of its grants, citing follow-up funding, startup companies, and FDA projects. 24:19 Jill highlights impactful partnerships and community initiatives, such as Jersey Mike's Day of Giving and the 100-Mile Challenge. 26:15 Details about the 100-Mile Challenge, including its structure and supporting events throughout September. 27:51 How CancerFree KIDS engages with families affected by cancer, ranging from support programs to events that honor children and their journeys. 29:51 The future direction of CancerFree KIDS, including expansion, collaboration, and advocacy efforts with the state of Ohio. 

Microsoft reportedly plans to begin using Anthropic's latest Claude models to power some of the Copilot features in its Office 365 apps. In a report published Tuesday, The Information said the tech giant would announce the change "in the coming weeks." Microsoft currently relies on OpenAI's tech to power the majority of AI features found inside of Word, Excel, Outlook and PowerPoint. Also, the FDA approved the biotech company eGenesis to begin human trials of pig-to-human kidney transplants. eGenesis provides pigs with CRISPR-modified genes. These genetic changes reduce the chances of organ rejection in human recipients. Learn more about your ad choices. Visit podcastchoices.com/adchoices

It's In the News.. a look at the top headlines and stories in the diabetes community. This week's top stories: CRISPR modified cell transplant for type 1, risk of T1D if parent has a different type of diabetes, Metformin and the brain, oral GLP-1, and more! Find out more about Moms' Night Out  Please visit our Sponsors & Partners - they help make the show possible! Learn more about Gvoke Glucagon Gvoke HypoPen® (glucagon injection): Glucagon Injection For Very Low Blood Sugar (gvokeglucagon.com) Omnipod - Simplify Life Learn about Dexcom   Check out VIVI Cap to protect your insulin from extreme temperatures The best way to keep up with Stacey and the show is by signing up for our weekly newsletter: Sign up for our newsletter here Here's where to find us: Facebook (Group) Facebook (Page) Instagram Twitter Check out Stacey's books! Learn more about everything at our home page www.diabetes-connections.com  Reach out with questions or comments: info@diabetes-connections.com Episode transcription with links: Hello and welcome to Diabetes Connections In the News! I'm Stacey Simms and every other Friday I bring you a short episode with the top diabetes stories and headlines happening now. XX A 42-year-old man who has lived most of his life with type 1 diabetes has become the first human to receive a transplant of genetically modified insulin-producing cells. This marks the first pancreatic cell transplant in a human to sidestep the need for immunosuppressant drugs. “This is the most exciting moment of my scientific career,” says cell biologist Per-Ola Carlsson of Uppsala University in Sweden, who helped develop the procedure. The new treatment, he says, “opens the future possibility of treating not only diabetes but other autoimmune diseases.” This procedure uses the gene editing technique, CRISPR, to discourage the auto immune attack on the donor cells. Before the transplant, the participant had no measurable naturally produced insulin and was receiving daily doses of the hormone. But within four to 12 weeks following the transplant, his levels rose slightly on their own after meals—showing that the new beta cells were releasing some insulin in response to glucose. even though the new study is promising, it involved just one participant and is therefore preliminary. And longer-term monitoring is needed to confirm the therapy's safety before it can be offered to more people. She also notes that the injected cells produced only 7 percent of the insulin needed for a person to be fully independent of additional medication. The researchers supplied the recipient with insulin doses to maintain healthy blood sugar levels. While Herold thinks it's still too early to consider this approach for a cure, “these options are now here to change the disease in ways that have never been possible before,” he says. “There's tremendous hope.” https://www.scientificamerican.com/article/type-1-diabetes-patients-insulin-production-restored-with-new-cell/ XX   This one is interesting… a recent study shows that children of mothers with gestational diabetes or fathers with type 2 diabetes have higher chances of developing type 1 diabetes than kids whose parents do not have any type of diabetes. Specifically, the study found that children whose mothers had gestational diabetes during pregnancy were 94% more likely to develop type 1 diabetes compared to children of mothers without diabetes. Similarly, having a father with type 2 diabetes was linked to a 77% higher risk. The study also suggests a possible link between maternal type 2 diabetes and type 1 diabetes in children, although more data are needed to confirm whether the risk is real.   "What is interesting is that type 1 diabetes is a disease of lack of the hormone insulin while gestational diabetes and type 2 diabetes stem mostly from the body's resistance to the hormone. What may be happening is that genes, environments and behaviors that create insulin resistance may also, in some cases, trigger the immune reactions that lead to type 1 diabetes," adds Dr. Dasgupta. A 2019 meta-analysis by researchers at Soochow University in China found that gestational diabetes was linked to a 66% higher risk of type 1 diabetes in children. This new study, which includes more than twice as many studies, offers a robust synthesis of current evidence and shows the risk is even greater than previously estimated. It is also the first meta-analysis to examine the link between paternal type 2 diabetes and type 1 diabetes in offspring. "Several mechanisms may be at play. Families often share lifestyle and eating habits, which can raise the likelihood that children will be affected. But beyond that, high blood sugar levels may also cause biological changes in parents that could increase their children's risk of developing type 1 diabetes," explains Laura Rendon, co-first author of the study, who completed an MSc in experimental medicine at The Institute and, as someone living with type 1 diabetes herself, finds deep personal meaning in conducting this research. For instance, the authors suggest that high blood sugar during pregnancy may stress the fetus's insulin-producing beta cells, reducing their number at birth or making them more vulnerable to damage later in life. It may also trigger epigenetic changes—modifications to proteins and molecules attached to DNA—that increase the risk. Likewise, high blood sugar in fathers with type 2 diabetes may cause epigenetic changes in their sperm, potentially influencing their child's risk of developing type 1 diabetes. https://medicalxpress.com/news/2025-08-diabetes-children-linked-parents.html XX Can a CGM help you lose weight? The company Signos is banking on it – the just got FDA approval for their system, which uses the over the counter Dexcom Stelo. The claim here is that the system will help track how food choices, activity, stress and sleep can all affect metabolism. Signos also works in partnership with the digital nutrition counseling startup Nourish. It currently offers a quarterly subscription plan, including six CGM sensors, for $139 per month. And they tell you don't take any medical actions based on the app's output without consulting a physician. https://www.fiercebiotech.com/medtech/fda-clears-signos-over-counter-cgm-powered-weight-loss-app XX Good news for T1D1, a free mobile app that helps people calculate insulin doses, track daily data, and share insights with healthcare providers. After being pulled off the market with similar apps a few years ago, it's now back and FDA approved. Drew Mendelow created the app after his diagnosis at age 13. He came on the show last year and I'll link his story up in the show notes. Diabetes Center Berne provided the initial funding to support the T1D1 efforts to redesign the app per FDA standards.  Comerge AG , the registered manufacturer, enlisted a team of software engineers, regulatory experts, and design professionals to ensure T1D1 was FDA-ready. Dexcom graciously conducted the Human Factors study to ensure safety and accuracy.  ​ ​T1D1 is now FDA-cleared as a Class II medical device and is the first over-the-counter insulin calculator cleared for individuals aged 2 and older. T1D1 is expected to be live in the AppStore and Google Play Store by October 2025. https://diabetes-connections.com/the-fda-took-down-this-teens-free-bolus-calculator-he-needs-your-help-to-bring-it-back/ XX Metformin has been the standard treatment for type 2 diabetes for more than six decades, yet scientists still do not fully understand how it works. A team from Baylor College of Medicine, working with international collaborators, has now identified an unexpected factor in its effectiveness: the brain. Their findings reveal a brain pathway involved in metformin's glucose-lowering action, pointing to new strategies for treating diabetes with greater precision. The study was published in Science Advances. The researchers concentrated on a small protein called Rap1, located in a region of the brain known as the ventromedial hypothalamus (VMH). They discovered that metformin's ability to lower blood sugar at clinically relevant doses depends on suppressing Rap1 activity in this brain area.   “This discovery changes how we think about metformin,” Fukuda said. “It's not just working in the liver or the gut, it's also acting in the brain. We found that while the liver and intestines need high concentrations of the drug to respond, the brain reacts to much lower levels.”     https://scitechdaily.com/after-60-years-scientists-uncover-hidden-brain-pathway-behind-diabetes-drug-metformin/   XX Looks like GLP-1 pills are moving ahead. Lilly says it's version helped overweight adults with type 2 lose 10% of their body weights and lower A1C. Just two weeks ago, we were talking about how the same drug in people without diabetes had less than the stellar expected results. Orforglipron is a small-molecule pill that is easier to manufacture and package than wildly popular injectable drugs for obesity, such as Lilly's Zepbound and Novo Nordisk's NOVOb.CO rival treatment Wegovy, which are peptide mimics of the appetite-controlling GLP-1 hormone. In the 72-week study of more than 1,600 overweight or obese adults with type 2 diabetes, those who received the 36-milligram highest dose of orforglipron on average shed 10.5% of their weight, or about 23 pounds (10.43 kg), versus 2.2% for those who received a placebo, achieving the main goal of the trial. Patients on the lowest 6 mg dose of the Lilly drug lost 5.5% of their weight. https://www.usatoday.com/story/news/health/2025/08/26/lilly-glp-1-pill-weight-loss/85830686007/ XX     An intervention that combined a low-calorie Mediterranean diet and exercise led to less diabetes incidence in older adults. Men had a greater diabetes risk reduction with the intervention than women. The study was based in Spain, and the diet may not be as easy to adhere to in the U.S. Among nearly 5,000 adults with metabolic syndrome and overweight or obesity in the PREDIMED-Plus trial, those who followed this intervention had a 31% lower risk for type 2 diabetes over 6 years relative to those who received only ad libitum Mediterranean diet advice (aHR 0.69, 95% CI 0.59-0.82). the Mediterranean diet focuses on high intake of plant-based foods, moderate consumption of fish, poultry, and dairy with optional red wine, and low intake of red meats, sweets, and sugar-sweetened beverages. Common foods featured in the diet include extra-virgin olive oil, fruits, vegetables, legumes, nuts, and whole grains. However, Sharon Herring, MD, MPH, and Gina Tripicchio, PhD, MSEd, both of Temple University in Philadelphia, pointed out that this study was conducted solely in Spain, and sticking to this type of diet may be more challenging in countries like the U.S.   "Participants in the study received extra-virgin olive oil to support adherence and retention; in the United States, prices of extra-virgin olive oil have nearly doubled since 2021 due to a combination of factors including climate change, rising production costs, supply chain disruptions, and now tariffs," they noted in an accompanying editorial. "[T]he large number of dietitian contacts during the study may prove difficult to scale broadly in the United States given challenges with health care access and reimbursement for prevention services."         https://www.medpagetoday.com/primarycare/diabetes/117151 XX A group of Canadian researchers has identified an unexpected way to lower blood sugar and protect the liver: by capturing a little-known fuel produced by gut bacteria before it enters the body and causes harm. The findings, published in Cell Metabolism, could open the door to new therapies to treat metabolic diseases like type 2 diabetes and fatty liver disease. Scientists from McMaster University, Université Laval, and the University of Ottawa discovered that a molecule generated by gut microbes can cross into the bloodstream, where it drives the liver to overproduce glucose and fat. By designing a method to trap this molecule in the gut before it reaches circulation, they achieved striking improvements in blood sugar regulation and fatty liver disease in obese mice. https://scitechdaily.com/scientists-discover-a-surprising-new-way-to-fight-diabetes/ XX Dexcom, which specializes in technology for glucose biosensing, will lay off 350 workers, with nearly 200 of them in San Diego, according to the San Diego Union Tribune. The bulk of the local jobs being lost are focused on Dexcom operations and manufacturing. The Dexcom development follows cutbacks to Verily, a life sciences company that is a subsidiary of Alphabet, Google's corporate parent. Verily's work included a project with Dexcom on wearable glucose sensors. CEO Stephen Gillett, in a memo obtained by the publication, said there will be “workforce reductions across Verily.” A representative for Verily confirmed to Business Insider that “we have made the difficult decision to discontinue manufacturing medical devices and will no longer be supporting them going forward.” https://timesofsandiego.com/business/2025/08/27/report-life-sciences-firm-dexcom-lay-off-200-san-diego-workers/ XX Front office changes at Insulet. Eric Benjamin, former chief product and customer experience officer, will take the role of chief operating officer, effective immediately. Manoj Raghunandanan Mu-NOHJ Rug-a-nun-da-nun to the position of chief growth officer, leading Insulet's new growth organization. The appointments are some of CEO Ashley McEvoy's first changes since she was hired in April. The appointments come after McEvoy outlined four priorities for Insulet on an August earnings call:   enhancing the company's commercial capabilities, building Insulet's brand and direct-to-consumer capabilities, driving growth outside of the U.S. and accelerating the pace of innovation. https://www.medtechdive.com/news/insulet-eric-benjamin-manoj-raghunandanan-appointments/758668/ XX   XX Want to highlight The Children's Diabetes Foundation in Colorado – they held a medal ceremony for patients of the Barbara Davis Center who've lived with Type 1 diabetes for 50 years or more. There were 87 medal recipients in the ceremony including Dana Davis, Executive Director of the Children's Diabetes Foundation and the daughter of the founders of the Barbara Davis Center. Davis shared: "When you got Type1 diabetes in the 70s, they thought you shouldn't have children. They thought you weren't going to live past 30 or 40. It was definitely very different," Davis said.   https://www.cbsnews.com/colorado/news/barbara-davis-center-celebrates-colorado-type-1-diabetes-patients-milestone/

If DNA is just a string of letters, could AI learn to read it … or even write it? Bioengineering researcher Eric Nguyen reveals how AI has upended the rules of biology, potentially creating a future where disease is cured with personalized medicine, extinct species are resurrected (Jurassic Park, anyone?) and microbes designed for Mars make interplanetary life possible. Learn more about how the world's first AI-designed CRISPR model successfully edited genes — and what it means for our understanding of life itself.For a chance to give your own TED Talk, fill out the Idea Search Application: ted.com/ideasearch.Interested in learning more about upcoming TED events? Follow these links:TEDNext: ted.com/futureyouTEDSports: ted.com/sportsTEDAI Vienna: ted.com/ai-viennaTEDAI San Francisco: ted.com/ai-sf Hosted on Acast. See acast.com/privacy for more information.

[01:00:44] EU Push for WarOpening monologue frames EU leaders' Oval Office visit as another step toward World War III, warning of elites driving conflict. [01:02:13] Chemo Costs & CorruptionKansas woman forced to sell baked goods for $10,000/month chemo illustrates Big Pharma greed and insurance industry corruption, with added discussion of chemo's brain damage. [01:20:33] Soros & Ukraine RevolutionsClips of George Soros admitting to funding Ukraine's revolution reinforce claims of Western-engineered regime change and manufactured conflict. [01:23:02] COVID Propaganda MachineActors and government PSAs compared to “I play a doctor on TV,” exposing taxpayer-funded psy-ops that pushed vaccines and lockdowns. [01:27:00] NATO & Endless WarsCriticism of NATO as an entangling alliance meant to drag the U.S. into European wars, with sanctions framed as acts of war. [01:42:00] Culture Wars: Tradwives & FuentesAnalysis of “tradwife” influencers like Lauren Southern and Nick Fuentes, accusing them of cosplaying tradition and discouraging real families, seen as controlled opposition undermining Western civilization. [02:25:03] Milo & the Right-Wing CircusDiscussion of Milo Yiannopoulos as an unstable provocateur, linked to Alex Jones, with comparisons to Laura Loomer; highlights the grifter culture. [02:25:44] AI as Modern IdolatryHealth Impact article sparks a segment framing AI as today's “talking idols,” reflecting human emptiness rather than true intelligence. [02:45:30] CRISPR & AI GeneticsConcerns raised that CRISPR gene editing is more like a chainsaw than a scalpel, with elites now turning to AI to “clean up” dangerous genetic manipulation. [02:49:19] De-Banking & StablecoinsDiscussion of Bank of America walking back “debanking” rules against religious groups, but warning that stablecoins are a Trojan horse for CBDCs and government financial control. [03:11:01] Trump Tariffs & Food CostsNew tariffs on Brazil, Switzerland, and Mexico predicted to raise prices on coffee, chocolate, olive oil, and groceries. Large corporations can absorb costs temporarily, but small businesses and consumers will feel the squeeze. [03:29:48] Israeli Official & Sex CrimesCoverage of an Israeli official caught in a Nevada sex crime sting but quietly returned to Israel, sparking discussion of influence, Epstein networks, and government protection of predators. [03:44:05] Pornography, AI & Spiritual WarAnalysis of how pornography addiction undermines churches, worsened by AI chatbots and virtual companions that manipulate users — framed as a spiritual battle for minds and families. Follow the show on Kick and watch live every weekday 9:00am EST – 12:00pm EST https://kick.com/davidknightshow Money should have intrinsic value AND transactional privacy: Go to https://davidknight.gold/ for great deals on physical gold/silverFor 10% off Gerald Celente's prescient Trends Journal, go to https://trendsjournal.com/ and enter the code KNIGHTFind out more about the show and where you can watch it at TheDavidKnightShow.com If you would like to support the show and our family please consider subscribing monthly here: SubscribeStar https://www.subscribestar.com/the-david-knight-showOr you can send a donation throughMail: David Knight POB 994 Kodak, TN 37764Zelle: @DavidKnightShow@protonmail.comCash App at: $davidknightshowBTC to: bc1qkuec29hkuye4xse9unh7nptvu3y9qmv24vanh7Become a supporter of this podcast: https://www.spreaker.com/podcast/the-david-knight-show--2653468/support.

[01:00:44] EU Push for WarOpening monologue frames EU leaders' Oval Office visit as another step toward World War III, warning of elites driving conflict. [01:02:13] Chemo Costs & CorruptionKansas woman forced to sell baked goods for $10,000/month chemo illustrates Big Pharma greed and insurance industry corruption, with added discussion of chemo's brain damage. [01:20:33] Soros & Ukraine RevolutionsClips of George Soros admitting to funding Ukraine's revolution reinforce claims of Western-engineered regime change and manufactured conflict. [01:23:02] COVID Propaganda MachineActors and government PSAs compared to “I play a doctor on TV,” exposing taxpayer-funded psy-ops that pushed vaccines and lockdowns. [01:27:00] NATO & Endless WarsCriticism of NATO as an entangling alliance meant to drag the U.S. into European wars, with sanctions framed as acts of war. [01:42:00] Culture Wars: Tradwives & FuentesAnalysis of “tradwife” influencers like Lauren Southern and Nick Fuentes, accusing them of cosplaying tradition and discouraging real families, seen as controlled opposition undermining Western civilization. [02:25:03] Milo & the Right-Wing CircusDiscussion of Milo Yiannopoulos as an unstable provocateur, linked to Alex Jones, with comparisons to Laura Loomer; highlights the grifter culture. [02:25:44] AI as Modern IdolatryHealth Impact article sparks a segment framing AI as today's “talking idols,” reflecting human emptiness rather than true intelligence. [02:45:30] CRISPR & AI GeneticsConcerns raised that CRISPR gene editing is more like a chainsaw than a scalpel, with elites now turning to AI to “clean up” dangerous genetic manipulation. [02:49:19] De-Banking & StablecoinsDiscussion of Bank of America walking back “debanking” rules against religious groups, but warning that stablecoins are a Trojan horse for CBDCs and government financial control. [03:11:01] Trump Tariffs & Food CostsNew tariffs on Brazil, Switzerland, and Mexico predicted to raise prices on coffee, chocolate, olive oil, and groceries. Large corporations can absorb costs temporarily, but small businesses and consumers will feel the squeeze. [03:29:48] Israeli Official & Sex CrimesCoverage of an Israeli official caught in a Nevada sex crime sting but quietly returned to Israel, sparking discussion of influence, Epstein networks, and government protection of predators. [03:44:05] Pornography, AI & Spiritual WarAnalysis of how pornography addiction undermines churches, worsened by AI chatbots and virtual companions that manipulate users — framed as a spiritual battle for minds and families. Follow the show on Kick and watch live every weekday 9:00am EST – 12:00pm EST https://kick.com/davidknightshow Money should have intrinsic value AND transactional privacy: Go to https://davidknight.gold/ for great deals on physical gold/silverFor 10% off Gerald Celente's prescient Trends Journal, go to https://trendsjournal.com/ and enter the code KNIGHTFind out more about the show and where you can watch it at TheDavidKnightShow.com If you would like to support the show and our family please consider subscribing monthly here: SubscribeStar https://www.subscribestar.com/the-david-knight-showOr you can send a donation throughMail: David Knight POB 994 Kodak, TN 37764Zelle: @DavidKnightShow@protonmail.comCash App at: $davidknightshowBTC to: bc1qkuec29hkuye4xse9unh7nptvu3y9qmv24vanh7Become a supporter of this podcast: https://www.spreaker.com/podcast/the-real-david-knight-show--5282736/support.

My guest is Dr. Sergiu Pașca, MD, professor of psychiatry and behavioral sciences at Stanford University. We discuss the biology and genetics of autism, why autism diagnoses are increasing and recent progress in using stem cells to understand and treat profound autism and other brain disorders. Dr. Pașca explains “organoids and assembloids”—human stem cell–derived tools he pioneered to study, treat and cure complex brain diseases. We also discuss ethical and safety issues with using gene editing and stem cells in humans. Read the episode show notes at hubermanlab.com. Thank you to our sponsors AG1: https://drinkag1.com/huberman David: https://davidprotein.com/huberman Helix: https://helixsleep.com/huberman BetterHelp: https://betterhelp.com/huberman Function: https://functionhealth.com/huberman Timestamps (00:00) Sergiu Pașca (02:08) Autism Spectrum Disorder, Incidence, Genetics (07:16) Is Autism More Common in Males? (09:35) Sponsors: David & Helix Sleep (11:56) Eye Contact in Babies, Fever; Proposed Causes of Autism; Genes (18:48) Genetic or Idiopathic Autism Diagnoses, Timothy Syndrome (21:37) Rise in Autism Diagnoses (26:46) Cause, Correlation & Neurological Disease; Schizophrenia, Do Vaccines Cause Autism? (31:34) Global Increase in Autism; Gene Therapy, CRISPR, Follistatin (41:05) Sponsors: AG1 & BetterHelp (43:41) Stem Cells, Ethics, Yamanaka Factors, Human Stem Cell Models (52:03) Umbilical Stem Cells; Stem Cell Injections & Dangers, Autistic Kids (59:30) Organoids, Modeling Brain Development, Intrinsic Development Timer (1:12:22) Assembloids, Brain Cell Migration & Circuit Formation, Self-Organization (1:21:22) Four-Part Assembloid, Sensory Assembloid, Pain Conditions (1:25:45) Sponsor: Function (1:27:33) Future Medical Therapies, Cell Banking, Immortalize Tissues, Rejuvenate Cells (1:34:56) Assembloids & Ethics, Importance of Nomenclature, Science Collaboration & Self-Correction (1:45:38) Cell Transplantation & Ethics, Timing (1:55:05) Genetic Testing for Parents, Genetic Penetrance (2:02:36) Assembloids, Timothy Syndrome, Epilepsy, Schizophrenia, Dystonia (2:14:30) Scientific Career, Walking, Art, Medical School (2:20:44) Zero-Cost Support, YouTube, Spotify & Apple Follow & Reviews, Sponsors, YouTube Feedback, Protocols Book, Social Media, Neural Network Newsletter Disclaimer & Disclosures Learn more about your ad choices. Visit megaphone.fm/adchoices

About this episode:  Sickle cell disease affects an estimated 100,000 people in the United States. Recent advancements in gene therapies and medicines like hydroxyurea are diminishing extreme pain, reducing strokes, and extending survival times for those afflicted by the disease. In this episode: leading sickle cell disease expert Dr. Mark Gladwin explains how revolutionary new treatments work and discusses the challenges to access to life-saving care. Guest: Dr. Mark Gladwin is a physician-scientist and the Dean of the University of Maryland School of Medicine and Vice President for Medical Affairs at the University of Maryland, Baltimore. His research focuses include sickle cell disease and hypertension. Host: Dr. Josh Sharfstein is vice dean for public health practice and community engagement at the Johns Hopkins Bloomberg School of Public Health, a faculty member in health policy, a pediatrician, and former secretary of Maryland's Health Department. Show links and related content: New sickle cell gene therapies are a breakthrough, but solving how to pay their high prices is a struggle—CNBC Gene Therapy: What You Need to Know—Sickle Cell Disease Association of American No More Pain: Breakthrough Sickle Cell Treatment from Johns Hopkins Offers Curative Potential—Johns Hopkins School of Medicine Transcript information: Looking for episode transcripts? Open our podcast on the Apple Podcasts app (desktop or mobile) or the Spotify mobile app to access an auto-generated transcript of any episode. Closed captioning is also available for every episode on our YouTube channel. Contact us: Have a question about something you heard? Looking for a transcript? Want to suggest a topic or guest? Contact us via email or visit our website. Follow us: @‌PublicHealthPod on Bluesky @‌JohnsHopkinsSPH on Instagram @‌JohnsHopkinsSPH on Facebook @‌PublicHealthOnCall on YouTube Here's our RSS feed Note: These podcasts are a conversation between the participants, and do not represent the position of Johns Hopkins University.

A Chinese scientist, He Jiankui, made a shocking announcement to the world in 2018: He had secretly engineered the birth of the first gene-edited babies. The birth of the twins was seen as reckless and unethical by the scientific community. That's because, among other things, the CRISPR gene-editing technique Jiankui used was so new. NPR science correspondent Rob Stein has been following the controversial world of gene-editing and human reproduction, including some companies' recent quests to push gene-editing technology forward.Read more of Rob Stein's reporting on the topic here.Interested in more science news? Let us know at shortwave@npr.org. Listen to every episode of Short Wave sponsor-free and support our work at NPR by signing up for Short Wave+ at plus.npr.org/shortwave.Learn more about sponsor message choices: podcastchoices.com/adchoicesNPR Privacy Policy